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ABSTRACT 
 
Background and aims: This study was carried out to compare the fasting plasma glucose 
(FPG)  and  2-h  plasma glucose  (2-h  PG)  criteria  for  diabetes  with  regard  to  their  relation  to  
stroke mortality and the incidence of ischemic and hemorrhagic stroke. In addition, the age-
and gender difference in the incidence of coronary heart disease (CHD) and stroke and their 
relation with known cardiovascular disease risk factors and diabetes mellitus was examined. 
Subjects and methods: The  study  was  a  sub-data  analysis  of  the  Diabetes  Epidemiology:  
Collaborative analysis Of Diagnostic criteria in Europe (DECODE) study including 25 181 
individuals, 11 844 (47%) men and 13 345 (53%) women aged 25 to 90 years, from 14 
European cohorts.  
Results:  In individuals without a history of diabetes elevated 2-h post-challenge glucose was 
a better predictor of stroke mortality than elevated fasting glucose in men, whereas the latter 
was better than the former in women.  Elevated FPG and 2-h PG levels were associated with 
an increased risk of ischemic stroke incidence. 2-h PG contributed to the risk more strongly 
than  FPG.  No  relationship  between  hyperglycemia  and  the  risk  of  hemorrhagic  stroke  was  
found. The risk of CHD and ischemic stroke incidence increased with age in both genders, but 
was higher in all age groups in men than in women. The gender difference was, however, 
more marked for CHD than for ischemic stroke. Age, smoking and diabetes contributed to the 
development  of  both  CHD  and  ischemic  stroke.  Elevated  cholesterol  levels  predicted  CHD  
only, whereas elevated blood pressure was a risk predictor for the incidence of ischemic 
stroke. The CHD and ischemic stroke risk was higher in men than in women with and without 
diabetes, however, the gender difference diminished for CHD but enlarged for ischemic 
stroke in diabetic individuals. The known risk factors including diabetes contributed 
differently to the risk of CHD and ischemic stroke in women and in men. 
Conclusion: Hyperglycemia defined by FPG or 2-h PG increases the risk of ischemic stroke 
in individuals without diabetes. FPG better predicts stroke mortality in women and 2-h PG in 
men. The risk of acute CHD and ischemic stroke is higher in men than in women in all ages, 
but such gender difference is more marked for CHD than for ischemic stroke. CHD risk is 
higher in men than in women, but the difference is reduced in diabetic population. Diabetes, 
however, increases stroke risk more in men than in women in all ages.  
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1. Introduction 
 
Ischemic heart disease and cerebrovascular diseases are the two leading causes of disability 
(World Health Organization, 2003) and death in the world (World Health Organization, 2003; 
Lopez et al. 2006; British Heart Foundation, 2008; World Health Organization, 2008). The 
death rates due to the two diseases are estimated to significantly increase by the year 2030 
(World Health Organization, 2008). There has been a clear decline in CVD incidence in the 
western industrialized countries (Kesteloot et al., 2006, Thom et al., 2006), however, in 
Europe cardiovascular diseases (CVDs) still account approximately half of overall mortality 
in both genders (British Heart Foundation, 2008). Up to 17% and 22-29% of the disability 
adjusted life years (DALYs) are lost due to CVDs in the western and eastern European 
countries, respectively (Allender et al., 2008).  
 
CHD and stroke are commonly discussed as two diseases with similar etiology caused by 
atherosclerotic vascular disease (Gulcher et al., 2005). CHD and stroke have been shown to 
share many common risk factors such as obesity, smoking, hypertension and aging. (Wolf et 
al., 1991; Njolstad et al., 1996a; Njolstad et al., 1996b; Jousilahti et al., 1999; Anand et al., 
2008; Jee et al., 2008). However, some differences have been reported in the risk factor 
profiles  of  the  two  diseases  (Wilhelmsen  et  al.,  2005).  Also,  some  well  known  CHD  risk  
factors, such as serum total cholesterol has not been found to have an association with 
increased risk of stroke (Bots et al., 2002; Wilhelmsen et al., 2005). Emerging evidence also 
indicate that the CHD and stroke risk factors may contribute differently to the development of 
atherosclerosis in different vascular sites in men and women (Debakey et al., 2000; 
Cimminiello et al., 2002; Eastwood et al., 2005; Iglseder et al., 2005; Kardys et al., 2007; 
Paraskevas et al., 2008; Sjölander et al., 2008).  
 
The incidence of CVD increases with age in both genders (Jousilahti et al., 1999). However, 
men generally develop CVDs approximately 10 years earlier than women (Bello et al., 2004; 
Anand et al., 2008). Even though, the risk of developing CVD is greater in men up to middle 
age (Rosamond et al., 2007), the gender gap decreases with advancing age (Rosamond et al., 
2008) and CVDs are a major cause of morbidity and mortality in both genders (Jousilahti et 
al., 1999; Seshadri et al., 2006; Bello et al., 2004; Pepine, 2004; Anand et al., 2008). Many 
factors either increase or decrease the risk of CVD (Kannel et al., 1961; Dobson et al., 1996). 
Known CVD risk factors such as hypertension, smoking, serum total cholesterol, diabetes and 
obesity are associated with increased risk of CHD (Jousilahti et al., 1999; Anand et al., 2008; 
Njolstad, 1996a) and stroke (Wolf et al., 1991; Njolstad et al., 1996b; Jee et al., 2008) both in 
women and in men. The known CVD risk factors are largely shared by both genders, 
however, some risk factors such as diabetes (Juutilainen et al., 2004), HDL-cholesterol and 
triglycerides (TGs) have been reported to have a greater impact on women (Shaw et al., 
2006). Also, a clear gender difference has been found in the development of atherosclerosis in 
different arterial sites in women and men (Eastwood et al., 2005; Kardys et al., 2007). 
 
Hyperglycemia has been found to be associated with many CVD risk factors (Glumer et al., 
2003) and it has been reported to increase CVD risk both in diabetic (Håheim et al., 1995; 
Fuller et al., 2001) and non-diabetic individuals (Perry et al., 1994; Balkau et al., 1998; de 
Vegt et al., 1999; Coutinho et al., 1999; DECODE Study Group, 2003a; Levitan et al., 2004; 
Meisinger et al., 2006a). Even though, studies have found a clear relationship between 
hyperglycemia and increased risk of CHD in diabetic individuals (Orencia et al., 1997; 
Balkau et al. 1998; The DECODE Study Group, 2001; Danaei et al., 2006) the association 
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between hyperglycemia and increased risk of stroke in non-diabetic individuals is not fully 
elucidated (Håheim et al., 1995; Qureshi et al., 1998; Hart et al., 1999).  
 
This  thesis  is  a  subdata  analysis  of  the  European  Diabetes  Epidemiology:  Collaborative  
analysis Of Diagnostic criteria in Europe study (DECODE), including 14 cohorts from five 
European countries.  The aim of the study was to compare the fasting plasma glucose (FPG) 
and  2-h  plasma glucose  (2-h  PG)  criteria  for  diabetes  with  regard  to  their  relation  to  stroke  
mortality and the incidence of ischemic and hemorrhagic stroke. In addition, the age-and 
gender difference in the incidence of coronary heart disease (CHD) and stroke and their 
relation with known cardiovascular disease (CVD) risk factors and diabetes mellitus was 
examined. 
 
2. Review of the literature  
2.1. Epidemiology of cardiovascular diseases  
CVDs are one of the leading causes of death worldwide. The main CVDs include CHD and 
stroke (British Heart Foundation, 2008; World Health Organization, 2008). In 2004 ischemic 
heart disease and cerebrovascular diseases accounted for 12.2% and 9.7%, of deaths 
worldwide, respectively. It is estimated that by the year 2030 the death rates from ischemic 
heart disease and cerebrovascular diseases (stroke) will increase and the two diseases will 
remain as the two leading causes of death in the world (World Health Organization, 2008). In 
the developing countries morbidity due to CVDs is double compared with that of the 
developed countries (World Health Organization, 2003) and the age-adjusted mortality related 
to CHD and stroke is increasing in some developing regions (Gaziano et al., 2007). A decline 
in CVD incidences has been seen in many western industrialized countries (Kesteloot et al., 
2006; Thom et al., 2006), however, in Europe CVDs still account for 43% of overall mortality 
in men and 54% in women (British Heart Foundation, 2008). Men are at greater risk of 
developing CVD compared with women up to middle age (Rosamond et al., 2007). However, 
the incidence of CVD in women increases with age and CVDs are a major cause of death in 
the elderly population in both genders (Jousilahti et al., 1999; Seshadri et al., 2006).  Studies 
have indicated that the earlier development of CVD in men can be due to a combination of 
several different factors such as hormonal, genetic and environmental (Mendelsohn et al., 
2005; Ordovas et al., 2007; Pilote et al., 2007). A number of risk factors including 
hypertension, smoking, serum total cholesterol, obesity and diabetes have been associated 
with increased CVD risk in both genders. (Wolf et al., 1991; Njolstad et al., 1996a; Njolstad 
et al., 1996b; Jousilahti et al., 1999; Anand et al., 2008; Jee et al., 2008). These risk factors 
may however, affect men and women differently (Pilote et al., 2007). Moreover, men are 
generally exposed to the known CVD risk factors earlier in life, which may partly explain 
why men develop a CVD approximately 10 years earlier than women. (Bello et al., 2004; 
Pepine, 2004; Anand et al., 2008).  
CHD and stroke are two diseases with common background and pathology often discussed as 
manifestations of atherosclerotic vascular disease (Gulcher et al., 2005). Many of the common 
CVD  risk  factors  are  shared  by  the  two  diseases,  however,  some  differences  in  risk  factor  
profiles for CHD and stroke risk has been reported (Wilhelmsen et al, 2005). Also, the 
patterns of the trend of CHD and stroke incidence have been shown to vary in a population 
(Kitamura et al., 2002; Truelsen et al., 2003). For example, the World Health Organization 
Multinational MONItoring of trends and determinants in CArdiovascular disease (WHO 
MONICA)  study has reported that while CHD rates have decreased, stroke rates have 
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increased in the same population, yet the opposite has been true for other populations 
(Truelsen  et  al.,  2003).  CHD  and  stroke  have  some  common  aspects,  yet  the  reactivity  of  
coronary and cerebral arteries with regard to the CVD risk factors, environmental and genetic, 
may differ. (Puddu et al., 1995; De Bakey et al., 2000; Paraskevas et al., 2008). This may in 
turn imply a different pathophysiology behind the two diseases. 
2.1.1. Classification of coronary heart disease and stroke 
2.1.1.1. Coronary heart disease 
 
CHD is caused by insufficient blood supply to the coronary circulation causing ischemia in 
the heart tissue. Carotid atherosclerosis is a strong predictor of ischemic heart disease 
(Johnsen et al., 2997). The presence of symptoms of myocardial ischemia, biochemical 
markers of myocardial necrosis, and electrocardiographical findings are important in 
diagnosis of the disease (Alpert et al., 2008). In the latest version of International 
Classification of Diseases-10 (ICD-10), an international standard diagnostic classification for 
diseases, ischemic heart disease is classified into angina pectoris, acute myocardial infarction, 
subsequent myocardial infarction, complications following acute myocardial infarction, other 
acute ischemic heart disease and chronic ischaemic heart disease (World Health Organization, 
2006).  
2.1.1.2. Stroke  
 
The clinical term stroke refers to three main categories of cerebrovascular diseases: 
thrombosis, embolism, and hemorrhage. Brain ischemia and infarction result from impaired 
blood flow and thus oxygenation to the brain whereas hemorrhage is caused by a rupture of 
the blood vessels in the brain (Frosch et al., 2005).  Stroke registers define stroke as “rapidly 
developed clinical signs of focal (or global) disturbance of cerebral function lasting more 
than 24 hours (unless interrupted by surgery or death), with no apparent cause other than a 
vascular origin” (WHO MONICA Manual, 1999; Tolonen et al., 2002). The main subtypes 
of stroke include ischemic and hemorrhagic stroke. The two stroke subtypes have different 
background and pathophysiology (Collins et al., 2007).  In the ICD-10 the cerebrovascular 
diseases include subarachnoid hemorrhage, intracerebral hemorrhage, other nontraumatic 
intracranial hemorrhage, cerebral infarction, stroke not specified as hemorrhage or infarction 
and occlusion or stenosis of precerebral or cerebral arteries, not resulting in cerebral 
infarction and other or sequlae of cerbrovascular disorders in diseases classified elsewhere 
(World Health Organization, 2006).  
Ischemic stroke  
 
Brain uses 20% of the body’s total oxygen consumption. Impaired or cessation of blood flow 
to the brain may result in brain ischemia due to a impaired oxygen flow to the brain tissue. 
This can result from the reduction of perfusion pressure in the brain or from an obstruction of 
one or more of the brain vessels or from both of the conditions together causing an ischemic 
stroke (Frosch et al., 2005). The causes for acute ischemic stroke are much more variable than 
for acute myocardial infarction (Fisher et al., 2008). Large-artery atherosclerosis, caused by 
atherosclerosis in the internal carotid or vertebral-basilar arteries (Fisher et al., 2005), small-
vessel disease with formation of microatheroma in deep, small penetrating arteries and 
cardioembolism are the main causes of acute ischemic stroke (Fisher et al., 2008). About 70 
to 88% of all strokes are ischemic (Foulkes et al., 1988; Thrift et al., 2001; Thom et al., 2006).  
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Hemorrhagic stroke  
Intracerebral hemorrhage 
 
Hemorrhagic stroke occurs as a result of rupture in a cerebral blood vessel, which causes  
bleeding into the brain tissue i.e. intracerebral hemorrhage (Collins et al., 2007). Intracerebral 
hemorrhage can occur at any site of the brain (Frosch et al., 2005). Hemorrhages most 
commonly occur in the cerebral lobes, basal ganglia, thalamus, brain stem and cerebellum 
(National Institute of Neurological Disorders and Stroke, 1990; Morris et al., 1999). 
Hypertension is a common cause for intracerebral hemorrhage (Qureshi et al., 1997; Woo et 
al., 2002; Ariesen et al., 2003). Intracerebral hemorrhage accounts for approximately 9 to 
15% of all strokes (Foulkes et al., 1988; Thrift et al., 2001;Thom et al., 2006).  
Subarachnoid hemorrhage 
 
The most common cause of subarachnoid hemorrhage is a ruptured saccular aneurysm. Other 
causes include vascular malformations, (National Institute of Neurological Disorders and 
Stroke, 1990; Frosch et al., 2005) hematologic disturbances (Frosch et al., 2005) and tumors 
(National Institute of Neurological Disorders and Stroke, 1990; Frosch et al., 2005). 
Approximately 3 to 13% of all strokes are due to subarachnoid hemorrhage (Foulkes et al., 
1988; Thrift et al., 2001; American Heart Association, 2006).  
2.1.2. Coronary heart disease and stroke in the general population  
 
The CHD mortality and incidence rates vary greatly between countries, but a clear male 
prominence can be observed throughout populations of different countries (Barrett-Connor et 
al., 1997). The CHD prevalence rises with increasing age in both genders. However, the rise 
is less pronounced in men compared with women aged 85 years and above (Ahto et al., 1998). 
The CHD incidence rates have declined significantly in many western industrialized countries 
(Immonen-Räihä et al., 1996; Rosamond et al., 1998; Yusuf et al., 2001). A recent Finnish 
cross-sectional health examination survey among Finnish adult population (aged >= 45 years) 
in 1980 and 2000 reported CHD prevalence to have decreased among individuals aged 45 to 
64 years (Kattainen et al., 2006). Similar results were found in another Finnish study   
including 1 250 Finns aged 65 to 74 years. A statistical significant decline from years 1978-90 
to 1997 in the prevalence of CHD was observed both in men (34.6 vs. 23.1) and in women 
(23.1 vs. 17.8) (Kattainen et al., 2002). The FINAMI study, a continuation of the Finnish 
Monitoring of Trends and Determinants in Cardiovascular Disease (FINMONICA project) 
examined trends in CHD mortality in women and men aged 35–64 years between years 1983 
and 1997. The study found the mean annual decline in CHD mortality to be 6.4% among men 
and 7.0% among women (Salonen et al., 2003). However, even though the overall prevalence 
of CHD had decreased in individuals aged >=45 years the Finnish cross-sectional health 
examination survey found an almost 20% increase in the total numer of individuals with 
CHD. The study also reported that the dominance of CHD prevalence in middle aged men had 
changed to elderly women (Kattainen et al., 2006). In Finland the CHD incidence rates have 
also been reported to have declined less in women aged <55 years compared with men of the 
same age (Lehto et al., 2007), but in contrast the prevalence of CHD to have declined more 
clearly among elderly women (aged 64 to 71 years) than elderly men (Hartikainen et al., 
2003).  The FINMONICA study found the clear decline in CHD mortality rates in Finland to 
be due to declines in the incidence, recurrence, and case fatalities of CHD, which could be 
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attributed to improved primary and secondary prevention measures as well as in acute 
coronary care (Salomaa et al., 1996).  
 
As with CHD, great variations exist in the stroke incidence and mortality rates across 
different populations and different countries (Wolfe et al., 2000; Truelsen et al., 2003). 
However, in most populations the stroke cases most commonly occur in individuals aged 64 
years and over (World Population Prospects, 2004). Both in women and in men the number of 
stroke cases increase with increasing age. Stroke rates are generally higher in men compared 
with women (Truelsen et al., 2006) except in individuals aged 75 years and above among 
whom stroke rates have been reported to be higher in women (Numminen et al., 1996; 
Thorvaldsen et al., 1999; Correia et al., 2004). The FINMONICA study reported a clear 
decline in stroke incidence and mortality in between 1983 and 1992 in women (-2.2% and -
4.7% per year, respectively) and men (-1.7% and -5.2% per year, respectively) in three 
provinces in Finland. The study included individuals aged 25 to 74 years (Tuomilehto et al., 
1996a). Similar results were found in the Danish MONICA Study including residents (ca.330 
000) of 11 municipalities in Copenhagen County (Thorvaldsen et al., 1999), aged 25 years or 
above. The age-adjusted stroke rates decreased 3.9% and 4.1% per year among men and 
women respectively during a 10-year period (from 1982 to 1991). However, the prevalence of 
stroke cases in the population remained largely the same due to an increased proportion of 
elderly people in the study population during the study period (Thorvaldsen et al., 1999).  
 
The International Stroke Incidence Collaboration Study including 11 studies from Europe, 
Russia, Australasia, and the United States, found no significant differences in the incidence of 
stroke subtypes between different geographical regions. However, the populations included in 
the study were nearly all western and consisted mainly of white individuals (Sudlow et al., 
1997), thus a similar study including more ethnic groups may provide different results. 
Studies have though, reported gender differences in the incidence rates of subtypes of stroke. 
The ischemic stroke and intracerebral hemorrhage have been reported to be higher in men 
than in women, and the rates of subarcahnoid hemorrhagic stroke higher in women than in 
men (Truelsen et al., 2006).   
 
CHD  is  the  most  common  cause  of  mortality  in  Europe  in  individuals  under  the  age  of  75  
years. CHD accounts for approximately 20% of all deaths from all causes in men and 19% in 
women before the age 75 years, accounting for over 900.000 deaths in Europe (British Heart 
Foundation, 2008). In Finland the risk from dying to CHD has declined since the 1970’s, 
however, CHD still accounts for 11% and 20 % of overall deaths in women and men aged 25 
to 75 years, respectively (Statistics Finland, 2007). Age standardized mortality from CHD in 
women and men (Figure 1a and Figure 1b) has declined in the European Union after the mid 
1980’s. The mortality trends are similar in USA and Japan. However, in most of the Eastern 
Europe CHD mortality has been rising in both genders (Levi et al., 2002).  
 
In Europe stroke accounts approximately 500,000 deaths in individuals under the age of 75 
years.  Of  death  from  all  causes  in  men  9%  and  in  women  8%  are  due  to  stroke  in  people  
under the age 75 years (British Heart Foundation, 2008). The age standardized mortality from 
cerebrovascular diseases has declined in the European Union in women (Figure 1c) and in 
men  (Figure 1d). The trends are similar in USA and Japan. However, in most Eastern 
European countries mortality from CVDs including cerebrovascular diseases has been 
increasing in both genders (Levi et al., 2002). 
 
 
 13 
Coronary heart disease  
 
 
a            Women                    b               Men  
      
                             
  
 
                                                               
                                                             Stroke        
 
                                
c             Women                     d               Men 
 
                           
                                         
              
 
Figure 1.  Age standardized (world population) mortality rates during the years 1965 to 1997 
from CHD and stroke in women (Figure 1a and Figure 1c) and men (Figure 1b and Figure 
1d) in the European Union, eastern European countries (Bulgaria, Czech Republic, Hungary, 
Poland, Romania, and Slovakia), the USA, and Japan (Modified from Levi et al., 2002).  
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2.1.3. Secular trend in the incidence and mortality from coronary heart disease and                       
stroke  
 
The WHO MONICA project measured CHD mortality trends in 37 populations around the 
world, including 29 European populations from the early 1980s over ten years (Tunstall-
Pedoe et al., 1999). The study included men and women aged 35-64 years. The most 
significant decrease in coronary-event rates in men occurred in three northern European 
populations with the greatest decline in North Karelia, Finland. The increase in coronary 
event rates both in male and female populations occurred mainly in Central and Eastern 
Europe and Asia (Tunstall-Pedoe et al., 1999). The FINMONICA study described a 55% 
decline in the incidence of myocardial infarction in men and 62% in women, and 66% and 
81% decline in CHD mortality, respectively between years 1972 to 1992 (Immonen-Räihä et 
al., 1996). A more recent Finnish study (Pajunen et al., 2004) examined the trends in CHD 
incidence and mortality in Finland during a 11-year period (from 1991 to 2001). The study 
found the average decline in fatal and nonfatal CHD events per year to be 5.2% among men 
and 6.1% among women (Pajunen et al., 2004). A clear decreasing trend in the CHD 
incidence and mortality has been observed in the western industrialized world over the past 30 
years (Immonen-Räihä et al., 1996; Rosamond et al., 1998; Yusuf et al., 2001).  However, in 
many Eastern European countries such as Ukraine, the Russian Federation and Hungary the 
trend has been increasing and they have one of the highest rates of CVD incidence and 
mortality in the world (Yusuf et al., 2001). 
 
A deep decline in stroke mortality has occured in many western industrialized countries (Gale 
et al., 1997; Sarti et al., 2000; Lawlor et al., 2002). However, recently in some countries the 
rate of the decline has been reported to slow down (Gillum et al., 1997; Sarti et al., 2000; 
Feigin et al., 2003). In most industrialized countries stroke mortality started to decline in the 
beginning of the 1950s and the decline clearly increased in the early 1970s. From 1970s to 
mid 1980s stroke mortality rates have fallen by 30 % in most western countries and over 50% 
in for example USA and Japan. However, in many Eastern European countries stroke 
mortality has remained stable or even increased. For example, in Poland and Hungary stroke 
mortality among men increased over 50% from 1970 to 1985 (Gale et al., 1997). A recent 
international epidemiological study (Sarti et al., 2000) based on WHO mortality data, 
examined secular trends in stroke mortality from 1968 to 1994 in individuals aged 35 to 84 
years. The study found great differences in stroke morbidity and mortality trends in different 
regions of the world. In most western countries a decline in stroke mortality was observed in 
the early 1970s, with further increase in the decline in the 1980s. The decline in stroke 
morbidity and mortality continued to the early 1990s. In some countries, for example Sweden 
and Danemark, the decline in stroke mortality trend slowed down by the end of the study 
period, especially in the last five years from 1989 to mid 1994. In countries that still had 
moderate to high stroke mortality rates between 1990 and 1994, for example Finland and 
Japan, a declining mortality trend was still observed. In some Eastern European countries, for 
example Poland and Bulgaria the stroke mortality trends among men were increasing during 
the  whole  study  period.  The  direction  of  the  stroke  mortality  trends  were  the  same for  both  
young people and the elderly population (in men r=0.85, p=0.0001 and in women r=0.85, 
p=0.0001), even though the relative change was smaller among the older people (Sarti et al., 
2000).  
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2.1.3.1. Gender, secular trend, coronary heart disease and stroke  
 
Gender difference related to CHD incidence and mortality is well known (Lerner et al., 1986; 
Jousilahti et al., 1999; Anand et al., 2008). A recent epidemiological study including six 
countries  (England  and  Wales,  Australia,  France,  Japan,  Sweden  and  the  United  States)  
examined secular trends in gender differences from CHD mortality in between 1947 to 1997. 
The  study  found  the  gender  difference  in  CHD  mortality  to  vary  over  time  and  
geographically. The high prevalence of CHD in the 20th century affected mainly men which to 
a large extent resulted from differences in risk factor profiles in men and women such as 
smoking, hypertension, alcohol use and fat consumption (Lawlor et al., 2001). The study 
concluded that the widely proposed protective effect of endogenous estrogen in women does 
not explain the gender difference in CHD development, but environmental factors are 
important (Lawlor et al., 2001).  
 
A gender difference in stroke risk has been reported in general population (Sarti et al., 2000; 
Truelsen et al., 2006). In countries where the stroke mortality trends (in individuals aged 35 to 
74 years), such as Poland and Bulgaria, have been increasing the trend has been found to be 
more favorable for women than for men. Similarly, in countries where the mortality trend has 
been declining the decline has been greater in women than in men. Still, the direction of the 
trend has been found to be the same in women and in men in individuals aged 35 to 74 years 
(r=0.95, p= 0.0001) and in individuals with advanced age 75 to 84 years (r=0.92, p=0.0001) 
(Sarti et al., 2000).    
2.2. Cardiovascular disease risk factors  
It is well established that certain factors either increase or decrease the risk of CVD (Kannel 
et al., 1961; Dobson et al., 1996).  Many risk factors such as hypertension, smoking, serum 
total cholesterol, diabetes and obesity have been associated with increased risk of CHD 
(Jousilahti et al., 1999; Anand et al., 2008; Njolstad, 1996a) and stroke (Wolf et al., 1991; 
Njolstad et al., 1996b; Jee et al., 2008) in both genders. Even though, many of the well-known 
CVD risk factors are shared by both genders, studies have indicated that many CVD risk 
factors such as diabetes (Juutilainen et al., 2004), high-density lipoprotein cholesterol (HDL-
cholesterol) and TGs have greater impact on women (Shaw et al., 2006). Emerging evidence 
show that the known CVD risk factors may affect different arterial sites differently (Debakey 
et al., 2000; Cimminiello et al., 2002; Paraskevas et al., 2008). A Swedish population based 
study with 28 years of follow-up, comprising of 7 400 Swedish men aged 47-55 years, found 
several differences regarding incidence, mortality, prognosis, and risk factors between CHD 
and stroke  (Wilhelmsen  et  al.,  2005).  Also,  the  WHO MONICA study  found CHD rates  to  
decrease while stroke rates increased in one population while in another population the 
opposite was observed (Truelsen et al., 2003). The findings would indicate different 
pathologies and thus different risk factor profiles behind the two diseases. Yet, another study, 
including 18 662 US male physicians aged 40-84 years, compared competing risk factors for 
CHD, stroke and venous thromboembolism. The study found that the known risk factors; 
hypertension, elevated cholesterol, diabetes, and smoking were comparable for CHD and 
stroke, but not for venous thromboembolism.  However, the risk factors in the study were 
self-reported, which could cause some bias in the measurements and also bias in analyzing the 
results (Glynn et al., 2005).  
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Recent evidence indicate that the known CVD risk factors contribute differently to the 
development of atherosclerosis and thus CVDs in women and men. (Eastwood et al., 2005; 
Iglseder et al., 2005; Kardys et al., 2007; Sjölander et al., 2008). In a population based study 
in Rotterdam, including 2 013 women and men, aged 55 years and above, gender differences 
in CVD by vascular site were compared by comparing degrees of atherosclerosis in different 
arteries. The study found that the gender difference in atherosclerosis was larger in coronary 
vessels than in other vascular sites. This gender difference was more pronounced in younger 
individuals, but remained present even in individuals of advanced age (Kardys et al., 2007). 
Furthermore, the Salzburg Atherosclerosis Prevention program, (a prospective study to 
evaluate the effect of genetic and metabolic factors in the development of atherosclerosis) 
including 1 001 men (aged 40 to 55 years) and 587 women (aged 50 to 65 years) found the 
metabolic syndrome, defined according to NCEP-ATPIII criteria (NCEP, 2001), to affect 
early atherosclerosis more profoundly in women than in men. The odds ratio (OR) for women 
was 2.05 [confidence interval (CI) 95% 1.17 to 3.59] and for men 1.11 (CI 95% 0.72 to 1.73). 
The analyses were adjusted for age, body mass index (BMI), low-density lipoprotein 
cholesterol (LDL-cholesterol) and smoking (Iglseder et al., 2005).  
2.2.1. Secular changes in risk factors for coronary heart disease and stroke 
 
The CVD risk factor trends vary by population and gender (Evans et al., 2001). The WHO 
MONICA project including 21 countries in four continents found variations in trends in the 
known CVD risk factors among populations both in women and in men. For example, 
cigarette smoking decreased in most populations in men, and increased in most populations in 
women especially in the eastern European countries. The total cholesterol levels decreased in 
approximately 50% of the male populations and majority of the female populations, but the 
10-year trend in BMI increased in half of the female and male populations (Evans et al., 
2001).  The changes in the classic risk factors have been proposed to explain part of the 
change in trends in CVD morbidity and mortality in populations.  Another WHO MONICA 
study including 38 populations from 21 countries examined the changes in trends in risk 
factors between mid-1980s to mid-1990s and to what extent these changes explain the 
changes in CHD incidence in women and men aged 35 to 65 years. The study found the 
overall variety in risk factor trends to be similar to CHD event rates. However, the study 
concluded that the change in coronary-event rates that could be explained by trends in the 
known CVD risk factors were low, approximately 15% for women and 40% for men 
(Kuulasmaa et al., 2000). A recent Finnish study found the CHD mortality rates to have 
declined approximately by 63% between years 1982 to 1997. The study found that 
approximately 23% of the decrease in mortality was attributed to improvements in treatment. 
The improvements in risk factor profiles explained approximately 52-72% of the reduction in 
CHD deaths during the study period (Laatikainen et al., 2005).  Similarly, the WHO 
MONICA study examining the trends in stroke incidence in 15 populations from nine 
countries in individuals aged 35 to 64 years, found the changes in trends in classic risk factors 
only partly to explain the variations in stroke trends in different populations. During the 10-
year study period, taking the time lag into account, approximately 9% of the variation of 
stroke rates in men and 36% in women could be explained by changes in risk factor trends.  
The study found the association between changes in classic risk factors and stroke trends to be 
more marked in women than in men (Tolonen et al., 2002).  
 
In the WHO MONICA study approximately two-thirds of the decline in CHD mortality was 
found to be due to decrease in incidence rates (possibly related to decrease in the risk factor 
levels)  and  one  third  in  case  fatality  (possibly  related  to  improved  coronary  care)  rates  
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(Tunstall-Pedoe et al., 1999).  Similar results were found in a study conducted in United 
Kingdom between early 1980s and 2000. Approximately 42% of the decrease in CHD 
mortality rates was attributable to better treatments and 58% to reductions in the known risk 
factors, mainly smoking, blood pressure and cholesterol levels (Unal et al., 2004).  Men 
generally develop CHD approximately 10-years earlier than women (Lerner et al., 1986; 
Anand et al., 2008). Several factors may play a role in the differences in CHD mortality and 
morbidity in women and men. A population based study including 14 786 Finnish men and 
women found gender differences in the known CVD risk factors to explain almost 50% of the 
gender related differences in CHD incidence and mortality. The study found the greatest 
difference in the risk factors between genders to be the HDL/total cholesterol ratio, but also a 
greater prevalence of smoking among men contributed to the the excess CHD risk in men 
compared with women (Jousilahti et al., 1999).  Other factors such as genetic predisposition 
together with environmental factors may affect the development of CVD in both genders 
(Ordovas et al., 2007; Pilote et al., 2007). The gender gap in CHD incidence and mortality 
diminishes with advancing age (Jousilahti et al., 1999; Rosamond et al, 2007; Andreotti et al., 
2008) and in the elderly population, at least partly due to the longer life span in women the 
number of CHD events is higher in women compared with age-matched men. Gender 
differences  in  CHD mortality  can  also  be  explained  by  the  different  treatment  strategies  for  
men and women with CHD. Women with CHD are often underdiagnosed and undertreated 
compared with men (Andreotti et al., 2008).  
 
The mortality rates for stroke and stroke subtypes differs with regard to gender (Sacco et al., 
1998; Ayala et al., 2001) and age (Ayala et al., 2001). Age- specific incidence and mortality 
rates are higher in men than in women. However, due to the longer lifespan in women stroke 
events are higher in elderly women compared with age-matched men (Sacco et al., 1997). In 
an epidemiological study among United States residents between years 1995 to 1998 
mortality rates (per 100 000 population) were calculated to compare gender- and age-
standardized death rates for ischemic stroke, intracerebral and subarachnoid hemorrhagic 
stroke. The study found the female-to-male ratio for stroke mortality to be 0.9 for ischemic 
stroke, 0.8 for intracerebral hemorrhage and 1.6 for subarachnoid hemorrhage. The age-
specific  mortality  rates  were  lower  for  women  than  for  men  under  the  age  of  65  years,  
however the mortality rates for ischemic stroke were higher in women in individuals over 65 
years. The risk of mortality from subarcahnoid hemorrhage was higher in women than in men 
across age groups and the gender difference increased with increasing age (Ayala et al., 
2002). Another study anlyzed the distribution of stroke subtypes in 1 581 individuals with 
first ever acute stroke in Barcelona between years 1995 to 2002. The study found no 
differences between ischemic (85.8% in women vs. 83.7% in men) and hemorrhagic stroke 
(14.2% vs.16.3% in men) with regard to gender. However, significant gender-differences 
were found in the incidence of subtypes of acute ischemic stroke classified according to 
TOAST (Trial of Org 10172) (TOAST, 1998). Women had more cardioembolic strokes and 
men more atherothrombotic and lacunar strokes. The study concluded that the greater 
frequency  of  known  atherosclerotic  risk  factors,  such  as  smoking  and  arterial  peripheral  
disease could explain the predominance of atherothrombotic strokes found in men in the 
study. Additionally, the higher percentage of cardioembolic strokes among women compared 
with men could be due to greater frequency of atrial fibrillation found in women. Other 
gender differences in risk factors in individuals suffering first ever acute stroke were the 
predominance of arterial hypertension in women, and excess alcohol use, smoking, and 
history of arterial peripheral disease in men. The study found no differences regarding 
diabetes, history of ischemic heart disease or hypercholesterolemia in between genders 
(Roquer et al., 2003).  
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2.2.2. Age 
 
CVD incidence and mortality has been found to increase with aging in both genders (Kannel 
et al., 1961; Jousilahti et al., 1999). Aging is one of the most significant risk factors for CHD 
(Jousilahti et al., 1999) and stroke (Wolf et al., 1992; Brown et al., 1996). Approximately  
82% of individuals who die of CHD are aged 65 years or above. Even though, the mortality 
risk from CHD in women lags 10 years behind men, the gender gap decreases with advancing 
age (Rosamond et al., 2008). Stroke rates more than double for every 10 years after the age 55 
in women and men (Wolf et al., 1992; Brown et al., 1996). The Framingham Study found the 
lifetime risk of stroke to be 1 in 6 or higher in individuals aged 55 to 75 years. The risk was 
higher in women (20% to 21%) than in men (14% to 17%), mainly due to the longer life 
expectancy in women. Elevated blood pressure significantly increased the lifetime risk of 
stroke (Seshardi et al., 2006). The Framingham study has found a fall in diastolic blood 
pressure and a rise in systolic blood in individuals above the age of 60 years. This is 
consistent with increased large artery stiffness due to aging and thus increased risk of CVD 
(Franklin et al., 1997). Furthermore, metabolic changes such as increased risk of insulin 
resistance, diabetes, changes in lipid metabolism and increase in BMI occur with aging, which 
all in turn are associated with increased CVD risk. (Barbieri et al., 2001; Wilson et al., 2002b; 
Zeeh et al., 2002; Schubert et al., 2006).  
2.2.3. Gender 
 
CHD rates vary greatly between different populations, however, the age-standardized male-
to-female ratio of 2.5 to 4.5 remains fairly consistent across populations (Barrett-Connor et 
al., 1997). The reasons for this gender gap are not fully known (Sytkowski, 1996; Jousilahti et 
al., 1999; Anand et al., 2008). The Framingham study examined 20-year trends in risk factors, 
incidence, and mortality among women and men aged 50-59 years. The study found that 
improvements in the known risk factors (cholesterol, blood pressure, diabetes, smoking and 
obesity) could explain approximately half of the 51% decrease in CHD mortality in women 
and one third to one half of the 44% decrease in men observed during the study period. 
However, these risk factors could not explain the observed gender difference in CHD 
incidence (Sytkowski, 1996). In another study consisting of 14 786 Finnish men and women, 
aged  25  to  64  years,  the  differences  in  risk  factors  between women and  men,  such  as  HDL 
cholesterol and smoking, explained almost 50% of the gender difference in CHD risk. The 
observed age related increase in CHD incidence and mortality in the study could be attributed 
to an increase in risk factor levels (serum total cholesterol levels, blood pressure, BMI, and 
diabetes prevalence) with advancing age in both genders. However, the risk factor related 
increase  in  CHD  with  age  was  more  pronounced  in  women  than  in  men  (Jousilahti  et  al.,  
1999). The INTERHEART study, a global case-control study, consisting of 27 098 
participants from 52 countries, examined the differences in risk factor profiles in women and 
men in different age groups to find out why women develop acute myocardial infarction 
approximately ten years later then men. The study found that in women the risk factors 
hypertension, diabetes, physical inactivity, and alcohol use more strongly predicted the 
development of acute myocardial infarction than in men. In the study the risk of acute 
myocardial infarction was significantly higher in men compared with women before the age 
of 60 years. However, when the analysis was adjusted for the risk factor levels present in 
women and men the gender difference was reduced by over 80%. The study concluded that 
the 10 year lag in acute myocardial infarction in women can be explained by higher levels of 
risk factors at a younger age in men compared with women (Anand et al., 2008). Furthermore, 
the  protective  effect  of  estrogen  has  been  proposed  to  be  correlated  with  decreased  risk  of  
 19 
CVD mortality and morbidity in premenopausal women compared with age-matched men 
(Klouche et al., 2006).  
 
The gender difference in the lifetime probability for CHD is greater than for total CVD in 
general population (Peeters et al., 2002). The risk of stroke is only slightly increased in men 
compared with women and the stroke incidence rates are approximately 1.25 times higher in 
men. Due to the longer lifespan in women the annual mortality rates are higher in women. 
(Sacco et al., 1997a; Peeters et al., 2002).  
2.2.4. Hyperglycemia and type 2 diabetes mellitus  
 
Diabetes mellitus is a disorder which is characterized by persistent elevated blood glucose  
levels in the body due to lack of insulin or insulin resistance in the periphery (World Health 
Organization, 1999). Diabetes has clearly been shown to increase the risk for CVD event in 
all age groups and both in women and in men (Kuller et al., 2000; Abbott et al., 2003; 
Juutilainen et al., 2004; Kissela et al., 2005; Barr et al., 2007). The prevalence of type 2 
diabetes is increasing among adults worldwide (Wild et al., 2004; Lusignan et al., 2005). 
 
Hyperglycemia refers to abnormalities in glucose metabolism that are most commonly 
measured with threshold criteria for fasting plasma glucose (FPG) or 2-h plasma glucose (2-h 
PG, measured two hours after a 75 gram oral glucose load). Patients with hyperglycemia are 
at increased risk of developing type 2 diabetes (Petersen et al., 2005) and CVD (Haffner, 
1998; Coutinho et al., 1999; de Vegt et al., 1999; DECODE Study Group, 2003 a). 
Hyperglycemia and diabetes are discussed in more detail below.  
2.2.5. Overweight and obesity 
Overweight and obesity are increasing in western societies (Berg et al., 2005; Bornstein et al., 
2008). Total body fat and visceral adiposity increase with age. The age related increase in 
adiposity is higher in women than in men (Poehlman, 1995). Obesity is associated with many 
CVD risk factors, such as hypertension (Reeder et al., 1992; Wilson et al., 2002a), 
dyslipidemia (Reeder et al., 1992) and diabetes (Reeder et al., 1992; Wilson et al., 2002b; 
Field et al., 2004; Meisinger et al., 2006b). Overweight and obesity are associated with 
increased risk of CVD (He et al., 2001; Wilson et al., 2002a). The Framingham study, with 44 
years of follow-up, examined association between BMI  (defined  as  weight  in kilograms 
divided by height in meter squared), cardiovascular disease risk factors and CVD end points 
in men and women aged 35 to 75 years. The primary outcome was first incident CVD event, 
including angina pectoris, myocardial infarction, CHD, and stroke.  The study compared 
individuals with overweight (BMI= 25.0-29.9) and obesity (BMI >=30) with individuals with 
normal weight (BMI= 18.5-24.9). Excess adiposity was found to be significantly associated 
with CVD events both in men [overweight; relative risk (RR) 1.21 (95%CI 1.05-1.40) and 
obesity; RR 1.46 (95%CI 1.20-1.77)] and in women [overweight; RR 1.20 (95%CI 1.03-1.41) 
and obesity RR 1.64 (95%CI 1.37-1.98)] (Wilson et al., 2002a). Similar findings were 
obtained in the NHANES I Epidemiologic Follow-up Study, a prospective cohort study of 
NHANES I with 19 years of follow-up. The study included 13 643 men and women aged 25 
to 74 years without a history of congestive heart failure at baseline.   The  study  found  a  
significant association between overweight (BMI >= 27.3 for women and BMI >= 27.8 for 
men) and increased risk of congestive heart failure both in women [RR 1.43 (95% CI 1.19-
1.72)] and in men [RR 1.24 (95%CI 1.01-1.51)].  The analysis was adjusted for age, race, and 
time-dependent history of CHD (He et al., 2001).  
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The relationship between adiposity and cerebrovascular disease is to some extent not fully 
elucidated (Jood et al, 2004; Song et al., 2004; Hu et al., 2007a). In a population based study 
consisting of 49 996 participants aged 25 to 75 years, from Finland elevated BMI was found 
to be a risk factor for total and ischemic stroke. The multivariate adjusted (age, study year, 
smoking, physical activity, educational level, family history of stroke, alcohol drinking) 
hazard ratio (HR) for each 1-U increase in BMI were 1.04 (95%CI 1.02-1.05) in women and 
1.05 (95%CI 1.04-1.07) in men. Abdominal adiposity defined as waist to hip ratio, was a risk 
factor  for  total  and  ischemic  stroke  in  men,  but  not  in  women.  In  women,  a  U-shaped  
association was found between hemorrhagic stroke risk and BMI (Hu et al., 2007a). Similar 
findings were obtained in the prospective Multifactor Primary Prevention Study in Sweden 
with 7 402 male participants aged 47 to 55 years with over a 28-year follow-up. The study 
found elevated BMI to be associated with increased risk of ischemic stroke in men with BMI 
>30.0, HR 1.78 (95% CI, 1.22-2.60). However, no association was found between BMI and 
hemorrhagic stroke risk. Analysis were adjusted for smoking, exercise, psychological stress, 
occupational class, and parental history of stroke (Jood et al. 2004). Also, in women obesity 
has  been  found  to  be  associated  with  ischemic  stroke  risk.  In  the  Nurses  Health  Study   
including 116 759 women aged 30 to 55 years elevated BMI was associated with increased 
risk of ischemic stroke RR varying between 1.75 (95% CI, 1.17-2.59), 1.90 (95% CI, 1.28-
2.82), and 2.37 (95% CI, 1.60-3.50) for BMI of 27 to 28.9, 29 to 31.9 kg/m2, and 2.37 (95% 
CI, 1.60-3.50), respectively. Weight gain from the age of 18 was associated with increased 
risk of ischemic stroke. No significant association was found between BMI and the risk of 
hemorrhagic stroke (Rexrode et al., 1997).  
In obese children CVD risk factors such as LDL-cholesterol, decreased levels of HDL- 
cholesterol, increased insulin levels and higher blood pressure, are more common compared 
with children with normal weight (Reinehr et al., 2006). Some but, not all studies (Lawlor et 
al., 2005a; Lawlor et al., 2006) have shown childhood obesity to be associated with increased 
risk of CVD in adult life (Gunnell et al., 1998).  
2.2.6. Smoking 
 
Increased mortality and disability in industrialized countries is related to smoking (Doll et al., 
1994; Mokdad et al., 2004). It is estimated that globally, in the year 2000, 4.83 million people 
died prematurely because of smoking (Ezzati et al., 2003). Smoking rates vary greatly 
between different countries and different populations. The prevalence of smoking is highest in 
the South-East Asia and Western Pacific regions and lowest in the African and American 
regions (World Health Organization, 2007). The WHO MONICA study including 37 
populations from 21 countries (individuals aged 35-64 years) reported the prevalence of 
smoking has been decreasing in majority of male populations while it was increasing in most 
of the female populations (Evans et al., 2001).  
 
Studies have indicated that the progression of atherosclerosis in the carotid arteries is directly 
related to total pack-years of tobacco exposure, which may be cumulative and irreversible. 
The Atherosclerosis Risk in Communities study, a population-based study with 10 914 
middle-aged adults from 4 communities in the United States enrolled between 1987 and 1989, 
found current cigarette smoking to be associated with 50%, past smoking with 25% increase 
and exposure to environmental tobacco smoke with 20% increase in the progression of carotid 
atherosclerosis when compared with nonsmokers.  The analysis were adjusted for for 
demographic characteristics, known CVD risk factors, and lifestyle variables such as physical 
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activity and alcohol use. The stduy found the association between smoking and 
atherosclerosis to be more marked in individuals with diabetes and hypertension (Howard et 
al., 1998a). The NHANES I Epidemiological Follow-up Study found daily cigarette smoking 
to be associated with increased risk of congestive heart failure. The risk was 88% increased in 
women  and  45%  in  men  (He  et  al.,  2001).  In  a  meta-analysis  consisting  of  32  studies,  
smoking was associated with a significantly increased risk of stroke. There were clear 
difference in stroke risk according to subtype. The risk for ischemic stroke was 1.9, for 
hemorrhagic stroke 0.7 and for subarachnoid hemorrhage 2.9 (Shinton et al., 1989).  
Furthermore,  smoking  has  been  found  to  have  a  graded  association  with  risk  of  type  2  
diabetes independent of other risk factors, age, BMI, physical activity, blood pressure, 
education and drinking coffee (Patja et al., 2005).  
 
Smoking cessation decreases CVD risk and CVD risk is reduced already one year after 
smoking cessation (Negri et al., 1994). The risk decreases to the levels of non-smokers within 
10 years (Negri et al., 1994; Al-Delaimy et al., 2001). Even though the benefits of smoking 
cessation are greatest when young, (<=35 years), smoking cessation even at middle age 
decreases smoking related mortality substantially (Doll et al., 1994). In addition to smoking 
cessation, the increased morbidity and mortality that characterize smokers may be further 
reduced by improvements in lifestyle behaviors such as diet and physical activity. 
(Hashizume et al., 2000; Bernaards et al., 2003; Haveman-Nies et al., 2003).  
2.2.7. Hypertension 
 
The incidence and prevalence of high blood pressure is increasing in general public (Lorenzo 
et al., 2002; Hajjar et al., 2003). The prevalence of hypertension increases with age (Franklin 
et al., 1997; Lorenzo et al., 2002; Vasan et al., 2002) and the residual lifetime risk of 
developing hypertension is 90% in individuals aged 55- to 65-years (Vasan et al., 2002). 
Hypertension is clearly related to CVD incidence (He et al., 2001) and mortality in long-term 
(Stamler et al., 1989; Antikainen et al., 1998; Hart et al., 1999; Miura et al., 2001; Lewington 
et al., 2002; Harmsen et al., 2006). A study including the World Bank regions (Europé, 
central Asia, Latin America and the Caribbean, Middle East and north Africa, south Asia, and 
sub-Saharan Africa, low-and middle-income regions of east Asia and Pacific, and high-
income regions worldwide) examined the blood pressure related burden of disease worldwide. 
The study found the burden to be large in all economies, but the proportion of burden 
attributable to high blood pressure to vary between different regions ranging from 4% to 35% 
for mortality and 2% to 20% for DALYs. The largest blood-pressure-related burden, for both 
mortality and DALYs, was found in Europe and central Asia, while it was smallest in sub-
Saharan Africa (Lawes et al., 2008).  
 
In older adults, prehypertension, defined as systolic blood pressure (SBP) from 120 to 139 
and diastolic blood pressure (DBP) from 80 to 89 mmHg, frequently progresses to 
hypertension during a period of four years (Vasan et al., 2001a). Prehypertension is less 
common in women than in men (prevalence 23% vs. 40%) (Wang et al, 2004). 
Prehypertension is associated with increased risk of CVD. The Framingham study found 1.5 
times (95% CI, 0.9 to 2.5) and 1.3 times (95% CI, 1.0 to 1.9) increased risk of CVD with SBP 
levels of 120 to 129 mmHg and DBP of 80 to 84 mmHg and 2.5 times (95% CI, 1.6 to 4.1) 
and 1.6 times (95% CI, 1.1 to 2.2) with SBP levels of 130 to 139 mmHg or DBP of 85 to 89 
mmHg in women and men, respectively (Vasan et al., 2001b). Hypertension is a significant 
risk factor for CHD risk in both genders (Jousilahti et al., 1999; Lawes et al., 2003). A clear 
association has also been shown between hypertension and ischemic (Lawes et al., 2003) and 
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hemorrhagic (Qureshi et al., 1997; Woo et al., 2002; Ariesen et al., 2003) stroke risk.  An 
approximately 80% increased stroke risk has been reported for every 10 mmHg increase in 
DBP (Prospective studies collaboration, 1995). However, with active hypertension treatment 
CVD incidence and mortality can be reduced in both genders (MRC, 1985; Staessen et al., 
1997; Preston et al., 2007). Even small long-term reductions in blood pressure such as 5-6 
mmHg DBP can reduce stroke risk over 35% (Collins et al., 1990), for individuals aged 60 to 
69  years  and  a  10  mm  Hg  reduction  in  SBP  decreases  CHD  risk  about  24%  (Lawes  et  al.,  
2003).  
 
Type 2 diabetes and elevated blood pressure often coexists (Gress et al., 2000; Isomaa et al., 
2001; Ball et al., 2003; Schrier et al., 2007). Studies have shown a strong relationship 
between elevated blood pressure and a risk of micro-and macrovascular complications in 
type 2 diabetes (Adler et al., 2000). Elevated blood pressure is a major risk factor for 
ischemic heart disease (Turner et al., 1998; Fuller et al., 2001) and stroke also in diabetic 
individuals (Fuller et al., 2001).  
2.2.8. Dyslipidemia 
 
Abnormal lipid levels are clearly correlated in the development of atherosclerosis (Levine et 
al., 1995; Kowalska et al., 2001). Several studies have shown a significant association 
between abnormal serum lipid levels and increased risk of CVD (Gardner et al., 1996; Isles et 
al., 2000; Anand et al., 2008). CHD risk is significantly increased in individuals with elevated 
plasma cholesterol, TG and LDL-cholesterol levels as well as low HDL-cholesterol levels. 
(Lamarche et al., 1995; Lamarche et al., 1996). Also, increased lipoprotein (a) levels have 
been found to be an independent risk factor for the development of coronary artery disease 
(Wild et al., 1997) especially in individuals with other known CVD risk factors such as 
obesity, type 2 diabetes, arterial hypertension and smoking (Zlatohlavek et al., 2008). Lipid 
abnormalities have also been shown to precede the onset of hypertension in nondiabetic 
individuals (Haffner et al., 1996; Halperin et al., 2006) and thus increase the risk of CVD. In a 
recent meta-analysis including 90 056 individuals from 14 studies, one mmol/l decrease in 
LDL-cholesterol levels using statin therapy was found to decrease the 5-year incidence of 
major coronary events and stroke by 20% (Baigent et al., 2005).  
 
Whether elevated serum cholesterol levels increase the risk of stroke is not fully elucidated 
(Papadakis et al., 1998; Wannamethee, 2000; Wilhelmsen et al., 2005). The Womens Health 
study including 27 937 women, examined the association between lipids levels and the risk 
of ischemic stroke in healthy middle-aged women aged ?45 years.  The study found a 
significant association between lipid levels and the risk of ischemic stroke in women. The 
multivariate adjusted HR’s (age, alcohol use, exercise, smoking, BMI, family history of 
myocardial infarction prior to age 60, current postmenopausal hormone use, history of 
diabetes, migraine status, cholesterol lowering medication use and randomized treatment 
assignments) for ischemic stroke risk with one millimole per liter-unit increase of 
cholesterol measures (38.7 mg/dL) were 1.17 (95% CI, 1.06-1.30) for total cholesterol and 
1.15 (95% CI, 1.01-1.31) for LDL-cholesterol (Kurth et al., 2007). Studies have also 
reported high TG levels (Freiberg et al., 2008) and low HDL-cholesterol levels to be 
associated with increased risk of ischemic stroke (Tanne et al., 1997; Simons et al., 1998). A 
recent Swedish study, with 28 years of follw-up, including  7 400 men (aged 47-55 years) 
compared risk factors for CHD and stroke incidence and mortality. The study found elevated 
serum cholesterol levels to be an independent significant risk factor for CHD RR 1.22 (1.17-
1.28), but not for stroke (Wilhelmsen et al., 2005). Similar results were found in the 
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Japanese collaborative cohort study (Cui et al., 2007) that examined the association between 
serum total cholesterol levels and the risk of CHD and stroke mortality.  The study included 
38 158 individuals (aged 40-79 years) and had ten years of follow-up. The multivariate 
adjusted (SBP, HDL-cholesterol, ethanol intake, smoking, and diabetes) OR were 3.74 (95% 
CI 1.11-12.6) for CHD, 0.87 (0.18-4.24) for ischemic and 0.12 (0.02-0.88) for hemorrhagic 
stroke for individuals with serum total cholesterol levels >=7.22 mmol/l (Cui et al., 2007). 
 
The lipid profile in diabetic individuals is often characterized with dyslipidemia, such as 
elevated TG levels, preponderance of LDL-cholesterol particles and decreased levels of HDL-
cholesterol (UKPDS, 1997; Betteridge, 2005). Studies have reported the diabetes related 
abnormal lipid profile to be more pronounced in women than in men (UKPDS, 1997; Howard 
et al., 1998b). Dyslipidemia is a major risk factor for CVD in diabetic individuals (Howard et 
al., 2000; Betteridge, 2005). 
2.2.9. Other risk factors  
C-reactive protein  
C-reactive protein (CRP) is used as a principal inflammatory marker of systemic low-grade 
inflammation in research and clinical practice (Pearson et al., 2003). Elevated CRP levels 
have been associated with increased risk of CHD (Koenig et al., 1999) and ischemic stroke 
(Rost et al., 2001) in individuals without history of CVD.  The Women's Health Study 
including 27 939 women found elevated CRP levels to better predict CVD risk comapred with 
elevated LDL-levels in women aged 45 years and above. The risk of cardiovascular event for 
women in the highest quintile of CRP (>=4.19 mg/L) was 2.3 (P<0.001) and for LDL-
cholesterol 1.5 (P<0.001). The analysis were adjusted for age, smoking status, diabetes status, 
blood pressure, and use or nonuse of estrogen (Ridker et al., 2002). In the MONICA Ausburg 
Study including 936 men aged 45 to 64 years the unadjusted HR for CHD risk with 1-SD 
increase in the log-transformed value of CRP was 1.67 (95% CI, 1.29 to 2.17).  Individuals 
with highest quintile of CRP (>=4.54 mg/L) had a 2.6-fold increased risk of a future coronary 
event (Koenig et al., 1999). Similar results were found in the Framingham Study examining 
the association between elevated CRP levels and the risk of ischemic stroke. The study 
included 591 men and 871 women without history of stroke or transient ischemic attack. The 
mean age of the participants was 69.7 years. Adjusting for age the RR for men in the 3rd CRP 
quartile (men 3.03 to 6.80 mg/L and women 3.20 to 7.31 mg/L) was 1.9 (1.04-3.61) and for 
women 1.8 (1.03-3.26) compared with those in the lowest quartile (Rost et al., 2001; Festa et 
al., 2000). Elevated CRP levels have also been associated with obesity (Yudkin et al., 1999), 
the metabolic syndrome (Ridker et al., 2003) and the risk of developing type 2 diabetes 
(Freeman et al., 2002), which have all been associated with increased risk of CVD (Wilson et 
al., 2002a; Johansen et al., 2003; Meeuwisse-Pasterkamp et al., 2008; Wang et al., 2007; 
Wang et al., 2008).   
Diet 
 
Dietary intake is a significant modifiable risk factor for CVD. In five cross-sectional 
population based surveys (in 1972, 1977, 1982, 1987, and 1992) in North Karelia, Kuopio and 
Turku in Finland it was observed that changes in nutrition such as reduction in total energy, 
saturated fat and cholesterol intake led to reductions in serum total cholesterol levels by 0.6 
mmol/liter in both women and men (Pietinen et al., 1996). Together with increase in fruit and 
vegetable intake, decreased smoking among men, and improvements in blood pressure control 
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and other CVD risk factors contributed to a three quarters decline in CHD mortality in these 
areas in Finland (Vartiainen et al., 1994; Pietinen et al., 1996). The Lipid Research Clinics 
Prevalence Study showed a significant independent association between increased total 
energy intake, increased percentage of energy intake from total fat, saturated fat, and 
monounsaturated fat and the risk of CHD mortality among women and men aged 30-59 years. 
The study also found that increased percentage of energy intake from carbohydrates has a 
protective effect against CHD in individuals without a history of CVD (Esrey et al., 1996).  A 
recent case-control study including 16 407 individuals from 52 countries, the INTERHEART 
study exmined the association between dietary patterns and the risk of acute myocardial 
infarction (AMI) worldwide. Three dietary patterns were identified; Oriental (with high 
dieatry intake of tofu, soy and other sauces), Western (dietary intake high in fried foods, salty 
snacks, eggs, and meat), and prudent (dietary intake high in fruit and vegetables). The study 
found higher levels of the prudent dietary intake to be protective against AMI. The 
association with Western dietary pattern and AMI was U-shaped, whereas no relationship was 
found between AMI and the Oriental dietary pattern. The study concluded that an unhealthy 
diet increases the risk of AMI and accounts for approximately 30% of the population-
attributable risk of AMI worldwide (Iqbal et al, 2008). Other nutrients such as fish (Whelton 
et al., 2004; He et al., 2004a) and antioxidants received e.g. by fruit and vegetable intake. 
(Knekt et al., 1996; Huang et al., 2002; Dauchet et al., 2006) have been shown to have 
cardioprotective effects. The combined report from the Nurses Health Study and the Health 
Professionals Follow-up Study  (Chiuve et al., 2008) found a significantly lower risk of 
stroke, escpecially ischemic stroke in individuals with a low-risk lifestyle (non-smoking, 
exercising daily, eating healthy diet, low alcohol intake, and normal weight during midlife) 
compared with individuals without a low-risk lifestyle. The study reported that in the two 
study populations, circa 50% of ischemic strokes could have been associated with unhealthy 
lifestyle factors (Chiuve et al., 2008). As for CHD, diet rich in fish (He et al., 2002; Iso et al., 
2001; Fung et al., 2004; He et al., 2004b; Mozaffarian et al., 2005), fruit and vegetables (Fung 
et al., 2004; Dauchet et al., 2005; He et al., 2006) and whole grains (Fung et al., 2004) has 
been found to decrease the risk of stroke (Ding et al., 2006).  
Physical activity  
 
Low levels of physical activity is associated with increased risk of CVD (He et al., 2001). 
Physical inactivity often coexists with overweight and obesity (Di Pietro et al., 1998) that are 
associated with many CVD risk factors (Reeder et al., 1992; Wilson et al., 2002a; Field et al., 
2004; Meisinger et al., 2006b) and thus with increased risk of CVD (He et al., 2001; Wilson 
et al., 2002a). Moderate to high levels of physical activity can reduce CVD risk                                         
substantially both in women and in men (Hu et al., 2000; Lee et al., 2003; Rothenbacher et al., 
2003; Barengo et al., 2004; Hu et al., 2005a). A Finnish Study including 47 721 individuals 
aged 25 to 64 years found high levels of leisure time physical activity (strenuous physical 
activity >3 h/week) to reduce the risk of all types of stroke. The multivariate-adjusted (age, 
sex, area, study year, BMI, SBP, cholesterol, education, smoking, alcohol consumption, 
diabetes, and other two types of physical activity) HRs were 0.80 (95% CI’s 0.68 to 0.93) for 
ischemic stroke, 0.63 (95% CI’s 0.42 to 0.95) for intracerebral hemorrhage and 0.46 (95% 
CI’s 0.27 to 0.76) for subarachnoid hemorrhage (Hu et al, 2005a). In  another  study  from  
Finland with 47 840 participants aged 25–64 years moderate to high levels of occupational or 
leisure-time physical activity were found to decrease CHD risk both in women and in men.  
The multivariate adjusted (age, study year, education, alcohol consumption, and smoking 
status, BMI, SBP, cholesterol, and history of diabetes) HRs for high leisure-time physical 
activity were 0.77 (95% CI’s 0.62–0.96) for women and 0.84 (95% CI’s 0.74–0.95)  for men 
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(Hu et al., 2007b). Overall CVD and all-cause mortality has been reported to decrease 2 to 
17% in women and 9 to 21% in men who are moderately (light physical activity >4 h/week) 
or highly (strenuous physical activity >3 h/week) physically active during leisure time 
(Barengo et al., 2004).  Furthermore, a recent exercise intervention trial study, the 
HERITAGE Family Study, found plasma CRP levels to decline in individuals with initially 
high CRP levels and sedentary lifestyles at baseline. The study included 652 subjects aged 17 
to 65 years. CRP decreased 1.34 mg/L in individuals with initially high CRP levels (>3.0 
mg/L) and remained the same in individuals with initially low CRP levels (<1.0mg/L) after 20 
week exercise program. The results remained significant after adjusting for other risk factors; 
weight, glucose and insulin levels, LDL-and HDL-cholesterol, TGs, SBP and DBP and 
maximal oxygen intake. These results further show the effectiveness of regular physical 
activity in CVD prevention and treatment (Lakka et al., 2005).  
Alcohol use 
 
Moderate alcohol use has been suggested to have protective affect against development of 
atherosclerosis and thus CVDs. (Kannel et al., 1996; Femia et al., 2006). Moderate alcohol 
consumption has been reported to have cardioprotective affects (Bryson et al., 2006; Maraldi 
et al., 2006). The Health, Aging, and Body Composition study found a significantly lower risk 
of cardiac events HR 0.72 (95% CI, 0.54-0.97) in light to moderate drinkers (1 to 7 drinks per 
week) compared with never or occasional drinkers (Maraldi et al., 2006).  
 
Recently the Swedish Women's Lifestyle and Health Cohort Study showed that in women 
under the age of 60 years who consumed moderate amounts of alcohol (20.0-69.9 g of alcohol 
per week) the risk of stroke was reduced to half compared with women who did not consume 
any alcohol (Lu et al., 2008).  A meta-analysis including 35 observational studies found 
consumption of < 12 g of alcohol/day, to be associated with a decreased RR for total stroke, 
0.83 (95%, CI, 0.75-0.91) and ischemic stroke, 0.80 (95% CI, 0.67-0.96) compared with 
nondrinkers. The study found a linear relationship between alcohol consumption and 
hemorrhagic stroke (Reynolds et al., 2003).  
 
Low to moderate levels of alcohol use may also decrease the risk of developing type 2 
diabetes mellitus (Ajani et al., 2000) and have blood pressure lowering effects (Gillman et al., 
1995; Fuchs et al., 2001; Sesso et al., 2008). However, the benefit of alcohol as a CVD 
protective agent is U-shaped (Maraldi et al., 2006). Heavy use of alcohol both increases blood 
pressure (Gillman et al., 1995; Sesso et al., 2008) and the risk of CVD in men and women in 
long term (Lin et al., 2005; Snow et al., 2009).  
Psychosocial factors  
 
It is well known that psychosocial factors contribute to the pathogenesis of atherosclerosis 
and the development of CVD (De Backer et al., 2003). Depression, hopelessness and work 
related stress are strongly related with the formation of atherosclerosis and CVD. (Everson et 
al., 1997; Lynch et al., 1997; Yamanaka et al., 2005). Women are more likely to have 
depressive disorders than men (Gorman et al., 2006). Depression however, is a significant risk 
factor for CVD in both genders (Ford et al., 1998; Ferketich et al., 2000; Yamanaka  et  al.,  
2005; Surtees et al., 2008a).  The United Kingdom European Prospective Investigation into 
Cancer-Norfolk study found a 2.7 times increased risk of ischemic heart disease in individuals 
with major depression compared with individuals without depression (Surtees et al., 2008a). 
Studies have also found an association between emotional distress (Surtees et al., 2008b), 
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depressive symptoms (Salaycik et al. 2007; Lee et al., 2008) and increased risk of stroke. The 
Baltimore Epidemiologic Catchment Area Study reported a 2.6 times increased likelihood of 
stroke in individuals with a history of depressive disorder (Larson et al., 2001).  
 
CVD risk factor levels and CVD mortality is higher among men and women in lower 
socioeconomic groups and with lower education level. (Mackenbach et al., 2000; He et al., 
2001; Yarnell et al., 2005; Metcalf et al., 2007). In the lower socioeconomic groups women 
and men are more often overweight (Machenbach et al., 2000; Molarius et al., 2000; 
Klumbiene et al., 2004; Anand et al., 2006), exercise less (Cirera et al., 1998), eat unhealthy 
food (Machenbach et al., 2000), are more often smokers (Cirera et al., 1998; Machenbach et 
al.,  2000;  Patja  et  al.,  2005)  and  especially  men consume more  alcohol  (Machenbach  et  al.,  
2000) compared with men and women in the higher socioeconomic groups. Studies have also 
reported lower socioeconomic status in childhood to be associated with CVD risk in later life 
(Kauhanen et al., 2006; Glymour et al., 2008). This effect has been found to be cumulative 
during lifecourse (Lawlor et al., 2005b).   
Family history of cardiovascular disease 
 
It  is  well  established that the development of CVD has hereditary components (Goldstein et  
al., 1973; Gallagher et al., 1996; Leander et al., 2001; Lloyd-Jones et al., 2004; Nilsson et al., 
2004; Murabito et al., 2005), for example the presence of apoE2 or apoE4 alleles has been 
found to increase the risk of CHD in men (Lahoz et al., 2001).  A case control study in 
Stockholm Sweden, including 1 091 men and 531 women with first-time acute myocardial 
infarction, aged 45 to 70 years, reported adjusted OR (age, residential area, smoking, ex-
smoking, job strain, physical inactivity, overweight, diabetes, hypertension, 
hypercholesterolemia and low socioeconomic status) for myocardial infarction to be 2.0 (95% 
CI, 1.6 to 2.6) in men and 2.1 (95% CI, 1.5 to 3.0) in women who had >=1 parent or sibling 
affected  with  CHD  compared  with  men  and  women  with  no  family  history  of  CHD.   The  
study also found synergestic interactions between family history of CHD and other known 
CVD risk factors, such as smoking and diabetes (Leander et al. 2001).  The association 
between family history of stroke and increased stroke risk is not as unequivocally described as 
that between CHD risk and family history of CHD.  The risk factor profiles for ischemic and 
hemorrhagic stroke subtypes were examined in a prospective observational study in Umbria, 
Italy including 2 395 patients with first-ever stroke incidence. The study found that 41.6% of 
the patients with ischemic stroke incidence had family history of stroke. For hemorrhagic 
stroke  incidence  family  history  of  stroke  was  not  a  significant  risk  factor  (Silvestrelli  et  al.,  
2006). In the Cohort studies of the National Survey on Circulatory Disorders, Japan, National 
Integrated Project for Prospective Observation of Noncommunicable Disease and its Trends 
in the Aged (the NIPPON DATA80) including 4 640 men and 5 906 women, aged ?30 years, 
no relation was found between a family history of stroke and the mortality from total stroke, 
cerebral infarction or intra-cerebral hemorrhage. However, the study found family history of 
hypertension, a known risk factor for stroke,  to be correlated with increased risk of total 
stroke mortality among women < 60 years (HR=3.41, 95% CI; 1.49 to 7.81) and in men > 60 
years (HR=1.50, 95% CI; 1.00 to 2.24) (Kadota et al., 2008).  
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2.3. Diabetes mellitus, intermediate hyperglcyemia and cardiovascular disease 
2.3.1. Definition and classification of intermediate hyperglycemia and diabetes  
 
Diabetes mellitus refers to a metabolic disorder that is characterized by hyperglycemia.  
According to WHO guidelines diabetes mellitus is defined as FPG levels >= 7.0 mmol/L and 
2-h PG levels >= 11.1 mmol/L (World Health Organization/International Diabetes Federation, 
2006).  Two major types of diabetes exists, type 1 and type 2. The onset of type 1 diabetes can 
occur at any age, but it is most common in younger individuals, children and young adults. In 
type 1 diabetes as a result of autoimmune destruction nearly all insulin secreting ?-cells in the 
pancreas are lost (Atkinson et al., 1994). Type 2 diabetes, which is more common in middle 
aged and older adults is characterized by impaired insulin secretion from ?-cells of the 
pancreas and of peripheral insulin action (for example in fat, muscle and liver) (Prokopenko 
et al., 2008). In diabetic individuals disturbances in insulin secretion or peripheral insulin 
resistance or both further leads to disturbances in carbohydrate, fat and protein metabolism 
(Atkinson et al., 1994; Prokopenko et al., 2008). The gastrointestinal hormones, gastric 
inhibitory polypeptide and glucagon-like peptide-1 have an important role in glucose 
homeostasis, promoting insulin biosynthesis, insulin secretion and islet beta-cell survival 
(Girard 2008). The glucose-lowering actions of gastric inhibitory polypeptide are unpreserved 
in subjects with type 2 diabetes (Drucker et al., 2003).  
 
The development of type 2 diabetes results from interaction between individuals genes and 
the environment (Ferrannini et al., 1998; Gloyn et al., 2001; Kahn, 2003; Stumvoll, 2005; 
Prokopenko et al., 2008). Obesity is a significant factor in the development of type 2 diabetes 
(National Heart Lung and Blood Institute, 1998). Mainly as a result of obesity type 2 diabetes 
generally results from defects in from both insulin secretion, due to ?-cell dysfunction, and 
insulin action (Prokopenko et al., 2008). Obese older adults have substantially increased risk 
of developing type 2 diabetes (Chang et al., 2003; Basu et al., 2003; Villareal et al., 2008) as 
aging is associated with decreased insulin secretion and increased peripheral insulin resistance 
(Chang et al., 2003; Basu et al., 2003). However, due to increasing prevalence of obesity in 
children and young adults type 2 diabetes is becoming more common also in younger age 
groups (Rosenbloom et al., 1999; Cali et al., 2008). Type 2 diabetes is a very common, 
chronic disorder and accounts for > 90% of diabetes globally (Stumvoll et al., 2005).  
Currently, the diagnostic criteria for type 2 diabetes has been accepted at a threshold at which 
micro-and macrovascular complications from diabetes become apparent. However, 
hyperglycemia related complications may be associated with a significantly lower threshold 
of glycemia than currently used for diagnosis for diabetes. Thus, two intermediate 
hyperglycemia categories, impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT) (World Health Organization, 1999; World Health Organization/International Diabetes 
Federation, 2006), have been introduced to refer to glycemic states with increased risk of 
developing type 2 diabetes. (Eldstein et al., 1997; World Health Organization, 1999; Qiao et 
al., 2003; Ferranini et al., 2004; Li et al., 2005; World Health Organization/International 
Diabetes Federation, 2006). IFG and IGT refer to metabolic states between normal glucose 
tolerance and diabetes and are currently defined according to World Health 
Organization/Internation Diabetes Federation 2006 diagnostic criteria as FPG levels 6.1 to 6.9 
mmol/l and 2-h PG levels <7.8 mmol/l for IFG and FPG levels <7.0 mmol/l and 2-h PG levels 
7.8 to 11.1 mmol/l for IGT (Table  1) (World Health Organization/International Diabetes 
Federation, 2006).   
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Table 1. The World Health Organization (WHO) and International Diabetes Federation (IDF) 
criteria for normal glucose level, intermediate hyperglycemia and type 2 diabetes mellitus.  
 
WHO& IDF, 2006   Fasting plasma glucose            2-h plasma glucose? 
Normal glucose  <6.1 <7.8 
Impaired fasting glucose >=6.1 and <6.9 <7.8 
Impaired glucose tolerance <7.0 >=7.8 and <11.1 
Diabetes mellitus >=7.0 >=11.1 
?Venous plasma glucose 2-h after ingestion of 75g oral glucose load. 
 
 
The intermediate states of hyperglycemia IFG and IGT represent physiologically different 
aspects of glucose metabolism. Fasting plasma hyperglycemia is the glucose concentration 
after an overnight fast and reflects abnormal hepatic glucose output and normal insulin 
resistance in the periphery and the liver, whereas postload hyperglycemia reflects acute 
increase in blood glucose level after a glucose load and is associated with decreased insulin 
secretion, normal to slightly reduced hepatic insulin resistance and increased insulin 
resistance in the periphery (especially in the skeletal muscle) (Davies et al., 2000; Unwin et 
al., 2002; Faerch et al., 2008).  
2.3.2. Prevalence of type 2 diabetes and intermediate hyperglycemia 
The incidence and prevalence of diabetes (Zimmet et al., 2001; Wild et al., 2004; Lusignan et 
al., 2005;  International Diabetes Federation, 2006) is increasing in general public.  In 2007 
the number of people with diabetes in adult population was estimated to be 246 million. 
Based on demographic changes like urbanization by the year 2025 the number of individuals 
with diabetes is estimated to rise to 380 million (International Diabetes Federation, 2008). 
The worldwide prevalence of diabetes is similar in men and women, being somewhat higher 
in men under the age of 60 years and in women at advanced age. Majority of individuals with 
diabetes in the developed countries are over the age of 64 years and in the developing 
countries between 45 to 64 years (Wild et al., 2004).  Individuals with diabetes generally have 
more CVD risk factors compared with nondiabetic individuals. For example obesity, 
increased blood pressure, and dyslipidemia are more common in individuals with diabetes. 
(Siegel et al., 1996; UKPDS, 1997).  
 
In most populations the prevalence of IGT is higher than IFG (Harris et al., 1997; Dunstan et 
al., 2002; DECODE Study Group, 2003b; Rathmann et al., 2003). A gender difference has 
been found in the prevalence of the two glucose categories IGT being more prevalent in 
women and IFG in men (Dunstan et al., 2002; DECODE Study Group, 2003b; Glumer et al., 
2003; Williams et al., 2003). The DECODE study (DECODE Study Group, 2003b), including 
13 studies from nine European countries, reported a moderate to low prevalence of diabetes 
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and impaired glucose regulation in European cohorts. IGT was found to be 1.2 to 1.6 times 
more prevalent in women and IFG 1.2 to 2 times more prevalent in men in individuals aged 
30 to 69 years. The study found the prevalence of impaired glucose regulation to increase 
with increasing age and to be under 15% in individuals aged 30 to 59 years and 25 to 30% in 
individuals over the age of 60 years in majority of the study cohorts. The increasing 
prevalence of impaired glucose regulation with aging resulted mainly from an increase in IGT 
rather than IFG in populations. In Europe diabetes was found to be undiagnosed in over 50% 
individuals under the age of 50 years. The prevalence of previously diagnosed diabetes was 
similar in both genders, however, in individuals aged > 80 years the prevalence was higher in 
women (DECODE Study Group, 2003b). The DECODE study group has further found that 
FPG and 2-h PG do not identify the same individuals and 31% of subject with diabetes remain 
undiagnosed if FPG alone is used for diagnosis of diabetes (DECODE Study Group, 1999). 
2.3.3. Association of type 2 diabetes with coronary heart disease and stroke 
 
Diabetes is associated with microvascular complications and diabetic individuals are at high 
risk of developing macrovascular diseases. CVDs account for circa two thirds of deaths in 
diabetic patients (Johansen et al., 2003; Meeuwisse-Pasterkamp et al., 2008). Table 2 presents 
recent epidemiological studies examining the association between type 2 diabetes and CHD 
and stroke risk. It is estimated that most individuals with type 2 diabetes have a manifest 
CVD or have a greatly increased risk of a CVD event in the future (Johansen et al., 2003). 
Diabetes  is  a  well-known  risk  factor  for  CHD  development  in  both  genders  (Sander  et  al.,  
2003; Howard et al., 2002; Imazu et al., 2002; Natarajan et al., 2003; Hu et al., 2005b). A 
recent meta-analysis reported the RR for CHD mortality from diabetes for women to be 2.58 
(95% CI 2.05-3.26) and for men 1.85 (1.47-2.33) (Lee et al., 2000).  
The association between diabetes and increased risk of stroke is well established (Lehto et al., 
1996; Tuomilehto, 1996; Wannamethee et al., 1999; Almdal et al., 2004; Kissela et al., 2005; 
Hu et al., 2005c; Hu et al., 2006; Mulnier et al., 2006). However, the reported magnitudes on 
RR vary greatly between different studies, from two to sixfold in women and from two to 
fourfold in men (Tuomilehto et al., 1996; Rodriquez et al., 2002; Almdahl et al., 2004; Iso et 
al., 2004). Type 2 diabetes is now regarded as CHD equivalent in the guidelines of National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NCEP ATPIII) 
(NCEP, 2001).  Even though the prevalence of diabetes increases with age, diabetes is a 
significant risk factor for stroke also in younger individuals (Abbott et al., 2003; Kissela et al., 
2005).  
Studies have reported diabetes related stroke risk to be more clearly associated with ischemic 
than hemorrhagic stroke rates (Karapanayiotides et al., 2004; Kissela et al., 2005). Many (Iso 
et al., 2004; Kissela et al., 2005; Janghorbani et al., 2007), but not all (Simons et al., 1998) 
studies have found a clear relationship between diabetes and ischemic stroke risk. However, 
studies on diabetes related hemorrhagic stroke risk have yielded conflicting results (Burchfiel 
et al., 1994; Jorgensen et al., 1994; Megherbi et al., 2003; Lund Håheim et al., 2006; Pham et 
al., 2007). In the Miyako Study including 9 651 participants (age >=40) history of diabetes 
was a significant risk factor for hemorrhagic stroke [HR 2.4 (95% CI 1.0- 5.8)], and total 
stroke  [HR  2.3  (1.5-  3.5)],  but  not  for  cerebral  infarction  [HR  1.5  (0.8-  3.1)].  The  analysis  
were adjusted for age, BMI, hypertension, sex, smoking, alcohol use, history of transfusion, 
vegetable and fruit consumption (Pham et al., 2007).  The Nurses Health Study including 116 
316 women (age 30-55 years) with 24 years of follow-up, found a significantly increased risk 
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of ischemic stroke in women with diagnosed diabetes compared with women without 
diabetes. However, the study found no association between diagnosed diabetes and 
hemorrhagic stroke risk. The multivariate adjusted (age, BMI, physical activity, menopausal 
status, estrogen use, smoking, hypertension, cholesterol, ischemic heart disease, aspirin use 
and alcohol use) RR were 2.3 (95 % CI 2.0-2.6)] for ischemic and 1.0 (95 % CI 0.7-1.4) for 
hemorrhagic stroke (Janghorbani et al., 2007). In the collaborative report from Honolulu 
Heart Study, including 7 589  Japanese-American, and the Framingham Study, with 1 216 
white men, aged 45 to 68 years, diabetes (diagnosed or nonfasting serum glucose level >12.5 
mmol/L after a 50-g glucose load), was associated with an increased risk of thromboembolic 
stroke in both Japanese-American [RR 1.9 (95% CI 1.5-2.4)] and white men [3.1 (1.6-5.8)]. 
Diabetes related hemorrhagic stroke risk increased in white [RR 4.5 (95% CI 1.3-15.8)], but 
not in Japanese-American men [RR 1.3 (0.8-2.0)]. The analysis were adjusted for age, 
hypertension, diabetes, total cholesterol levels, BMI, smoking, and alcohol intake (Rodriquez 
et al., 2002). A Swiss study, consisting of 4 064 individuals encoded in the Lausanne Stroke 
Registry between years 1983 and 2002, found diabetic (defined as history of diabetes or as 
FPG level >=7.0 mmol/L) individuals to have a lower relative prevalence of intracerebral 
hemorrhage [OR 0.63 (95% CI 0.45-0.9)] compared with nondiabetic individuals after 
multivariate adjustement for sex, age, smoking, hypercholesterolemia and hypertension 
(Karapathynies et al., 2004). Similarly, the European BIOMED I study found that diabetic 
patients were less likely to have hemorrhagic stroke than nondiabetic patients, 8.5% vs 11.5%. 
The study included 12 centers in 7 European countries with 4 537 patients with first ever 
stroke (Megherbi et al., 2003).  The Copenhagen Stroke Study, including 536 men and 633 
women with first ever acute stroke, found hemorrhagic stroke rates to be six times less 
frequent (p=0.002) in diabetic individuals compared with individuals without diabetes 
(Jorgensen et al., 1994).   
2.3.3.1. Gender, type 2 diabetes, coronary heart disease and stroke  
 
Several, but not all studies (Kanaya et al., 2002; Oba et al., 2008) have found diabetes to 
increase CHD risk more markedly in women than in men (Hu et al., 2005b; Huxley et al., 
2006; Juutilainen et al., 2004). In women history of diabetes has been found to be a more 
significant CHD risk factor than a history of CHD, whereas in men the opposite has been 
observed (Natarajan et al., 2003). A recent Finnish study including 478 women and 581 men, 
aged 45 to 64 years, found diagnosed diabetes to be a more significant risk factor for CHD in 
women than in men. The multivariate adjusted HR (adjusted for smoking, BMI, SBP, total 
cholesterol, HDL-cholesterol, logTG) for CHD event were 9.5 (95% CI 5.4 to 16.9) in women 
and 2.8 (95% CI 2.1 to 3.7) in men (Juutilainen et al., 2004). In another Finnish study 
including 51 735 individuals, aged 25-75 years, the RR for CHD mortality (adjusted for 
adjusted for age, study year, BMI, SBP, total cholesterol and smoking) were 4.9 (3.8-6.2) for 
women and 2.1 (1.7-2.6) for men with diagnosed diabetes (Hu et al., 2005b). However, a 
meta-analysis including 8 prospective studies found that the stronger diabetes related RR 
[women  2.9  (95%  CI  2.2  to  3.8)  and  men  2.3  (1.9  to  2.9)]  for  CHD  was  absent  after  
adjustment for known CHD risk factor. In the study diabetes was defined by self-report, use 
of a diabetic medication, physician documentation in medical records, or fasting or 2-hour 
postchallenge glucose criteria (Kanaya et al. 2002). The DECODE study has reported similar 
results (Balkau et al., 2004). The Takayama Study, a recent Japanese prospective study 
consisting of 13 335 men and 15 724 women aged >=35 years found diagnosed diabetes to 
increase the risk of CHD mortality in men [RR 2.96 (95% CI 1.59 to 5.50)], but not in women 
[RR 0.49 (0.07 to 3.57)]. The analysis were adjusted for age, smoking, BMI, physical activity, 
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length of education, history of hypertension, total energy intake and intake of vegetables, fat 
and alcohol (Oba et al., 2008). 
 
Several studies have found greater diabetes related stroke risk in diabetic women compared 
with diabetic men (Lehto et al., 1996; Tuomilehto et al., 1996; Har et al., 2000; Almdal et al., 
2004; Iso et al., 2004). The Copenhagen City Heart Study found a 2- to 6.5-fold increased risk 
of stroke in diabetic women and 1.5- to 2-fold in diabetic men compared with individuals 
without diabetes . The analysis were adjusted for tobacco consumption, physical activity 
alcohol consumption, BMI, TGs and total cholesterol levels. The study included 13 105 
subjects, aged 55 to 64 years, and had a 20 year follow-up (Almdal et al., 2004). Similar 
results have been found in two Finnish studies that found the diabetes-related stroke risk to be 
more marked in women than in men (Lehto et al., 1996; Tuomilehto et al., 1996).  A study 
including 1 059 diabetic men and women and 1 373 nondiabetic control subjects, aged 45 to 
64 years, from Eastern and Western Finland, found diabetic men to have a two to threefold 
greater and diabetic women a fivefold greater risk of stroke compared with non-diabetic 
individuals (in men: OR 2.4 [95% CI, 1.2 to 4.9] in East Finland and  3.3 [1.6 to 6.9] in West 
Finland, in women: OR 5.5 [2.4 to 12.9] in East Finland and 5.4 [2.3 to 12.6] in West 
Finland)  (Lehto  et  al.,  1996).  Another prospective study (mean follow-up 16.4 years) from 
Eastern Finland, including 8 077 men and 8 572 women, found 16% of stroke deaths to be 
related to diabetes in men and 33% in women (Tuomilehto et al., 1996). Increased diabetes-
related stroke risk was also reported in the Renfrew-Paisley Study.  The multivariate adjusted 
RR for stroke mortality were 2.89 (95% CI 1.49-5.62) for men and 3.98 (2.29-6.91) for 
women. The study included 7 052 men and 8 354 women, aged 45 to 64 years (Hart et al., 
2000).  
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Table 2. Relative risk (95% CI) coronary heart disease (CHD) and stroke in relation to diabetes as compared with non-diabetics in recent 
prospective studies.  
Study  Follow-
up (yrs) 
Diabetes 
definition 
Population, age 
(yrs) 
CHD 
mortality/  
event 
Overall stroke 
incidence  
/mortality 
Ischemic 
stroke 
incidence 
/mortality 
Hemorrhagic  
stroke 
incidence 
/mortality 
Reference  
North Karelia 
and Kuopio 
cohorts 
16.4 
(mean) 
diagnosed 
diabetes  
8 572 women       
8 077 men,        
age 30 to 59 
 women           
4.89 (2.83-8.45)    
men                
3.35 (1.96-5.73) 
  Tuomilehto 
et al., 1996 
The 
Honolulu 
Heart Study 
and The 
Framingham 
Study 
20 non-fasting 
serum glucose 
after a 50-g 
load or history 
of non-fasting 
levels 
7 589 Japanese-
American men        
1 216 white men,              
age 45 to 68 
  Japanese-
American     
1.9 (1.5-2.4) 
white          
3.1 (1.6-5.8)   
Japanese-
American   
1.3 (0.8-2.0) 
white          
4.5 (1.3-15.8)    
Rodriguez 
et al., 2002 
The 
Framingham 
Heart Study 
and the 
Framingham 
Offspring 
Study  
20 fasting plasma 
glucose, 
plasma 
glucose or 
diagnosed 
diabetes 
2 749 women      
2 494 men,       
age 35-74  
women          
3.8 (2.2-6.6) 
men               
2.1 (1.3-3.3) 
 
   Natarajan  
et al., 2003  
The 
Copenhagen 
City Heart 
Study  
20 non-fasting 
plasma 
glucose or 
diagnosed 
diabetes  
7 198 women      
5 907 men,        
age >=20 
women         
1.5-4.5         
men              
1.5-2.0  
women            
2.0-6.5            
men                 
1.5-2.0  
 
  Almdal      
et al., 2004     
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Five 
Japanese 
study cohorts         
17 fasting or 
non-fasting 
serum 
glucose, 
diagnosed 
diabetes 
6 295 women      
4 287 men,        
age 40-69 
 
  women             
2.2 (1.2–4.0) 
men                  
1.8 (1.0–3.2) 
 Iso et al., 
2004 
Finnish study 
cohort  
13  diagnosed 
diabetes  
478 women     
581 men,          
age 45-64  
women          
9.5 (5.4 -16.9) 
men               
2.8 (2.1- 3.7)  
   Juutilainen 
et al., 2004 
Finnish study 
cohort  
17.2 
(mean)  
diagnosed 
diabetes  
26 520 women   
25 215 men,     
age 25-75  
women          
4.9 (3.8-6.2) 
men               
2.1 (1.7-2.6) 
 
   Hu et al., 
2005b 
The Nurses 
Health Study 
26 
 
diagnosed 
diabetes 
116 316 women, 
age 30–55  
 
 
 
1.8 (1.7–2.0) 2.3 (2.0–2.6) 1.0 (0.7–1.4) Janghorbani 
et al., 2007 
The Miyako 
Study 
13.8 
(mean) 
diagnosed 
diabetes 
5 397 women      
4 254 men,       
age >=40 
 
 2.3 (1.5- 3.5) 1.5 (0.8- 3.1) 2.4 (1.0- 5.8) Pham et al., 
2007 
Takayama 
Study  
7 diagnosed 
diabetes 
15 724 women 
13 335 men,     
age >=35  
women          
0.5 (0.1 -3.6) 
men             
3.0 (1.5 - 5.5) 
   Oba et al., 
2008 
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2.3.4. Association of intermediate hyperglycemia  
         with coronary heart disease and stroke  
 
Diabetes  is  a  well  known  risk  factor  for  CVD  (Tuomilehto  et  al.  1996;  Lowe  et  al.,  1997;  
Natarajan et al., 2003; Hu et al., 2005b). Table  3 presents recent epidemiological studies 
examining the association between hyperglycemia and CHD and stroke risk. Hyperglycemia 
is associated with many CVD risk factors (Glumer et al., 2003) and some, but not all (Qureshi 
et al., 1998) studies have reported elevated glucose levels to predict CVD incidence also in 
nondiabetic individuals (Perry et al., 1994; Balkau et al., 1998; de Vegt et al., 1999; Coutinho 
et al., 1999; DECODE Study Group, 2003a; Levitan et al., 2004; Lawlor et al., 2007). A 
recent overview of epidemiological studies and surveys from 52 countries found 21 % of 
deaths from ischemic heart disease and 13% of stroke deaths to be associated with higher than 
optimum blood glucose levels (Danaei et al., 2006). Other studies have found similar results 
(Balkau et al. 1998; The DECODE Study Group, 2001). In a pooled analysis from three 
cohort studies with non-diabetic men, the Whitehall Study (10 025 men), the Paris 
Prospective study (6 629 men) and the Helsinki Policemen Study (631 men) a significantly 
increased risk of CHD mortality was found in the top 2.5% of 2-h blood glucose distribution 
(Balkau et al., 1998). However, not all studies have confirmed these findings. The Third 
National Health and Nutrition Examination survey (from 1988 to 1994) in the United States 
found no association between hyperglycemia (defined by FPG >140 mg/dl or 2-h PG >200 
mg/dl) and the incidence of myocardial infarction. The multivariate adjusted (age, sex, 
education, race/ethnicity, hypertension, cholesterol, BMI, smoking) OR was 0.9 (95% CI 0.5-
1.6). The study included 6 547 participants aged 40 to 74 years (Qureshi et al., 1998).  
 
The association between hyperglycemia and increased risk of stroke in diabetic individuals is 
well established (Håheim et al., 1995; Fuller et al., 2001). However, studies have provided 
conflicting results regarding the association between hyperglycemia and risk of stroke in 
nondiabetic individuals (Håheim et al., 1995; Qureshi et al., 1998; Wannamethee et al., 1999; 
Hart et al., 1999). As for CHD incidence the Third National Health and Nutrition 
Examination survey (above) found no association between stroke incidence and impaired 
glucose tolerance (defined by FPG or 2-h PG levels) in individuals without diabetes.  The 
multivariate adjusted OR for stroke incidence was 0.9 (95% CI 0.5-1.6) (Qureshi et al., 1998). 
Similar findings were obtained in the Oslo Study (Håheim et al., 1995). The RR (adjusted for 
age) for stroke incidence was 1.02 (95% CI 0.83 to 1.26) in men without diabetes. The study 
included 16 209 men aged 40 to 49 years and had 18-years of follow-up (Håheim et al., 
1995).  In the Honolulu Heart Program, including 7 549 Japanese-American men aged 45 to 
68 years an increased risk of thromboembolic [RR (adjustment age, BMI, hypertension, left 
ventricular hypertrophy, cholesterol, TGs, uric acid, hematocrit, smoking alcohol use, 
physical activity index) 1.43 (95% CI 1.00-2.04)], but not hemorrhagic stroke [0.96 (0.51-
1.82)] was found with high serum glucose levels (>=225 mg/dl) defined by 1-h postload 
glucose measurement compared with indivduals with normal glucose levels (<151 mg/dl). 
The study had a 22-year follow-up (Burchfiel et al., 1994). In a more recent study, the Turku 
Elderly Study, with 1 032 indivduals aged 70 years individuals with IGT (defined by 2-h 
plasma glucose levels between 7.80 and 11.09 mmol/l) had more stroke incidences compared 
with normal group, but the difference was not statistically significant (Kaarisalo et al., 2006). 
The association between hyperglycemia and stroke events is thus less clearly established than 
that between hyperglycemia and CHD. However, a clear correlation has been found between 
hyperglycemia and stroke outcome. It has been found that both individuals with and without 
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diabetes have worsened stroke outcome with admission hyperglycemia (Moulin et al., 1997; 
Capes et al., 2001). Impaired glucose tolerance has also been found to increase stroke 
recurrence in patients with transient ischemic attack or minor ischemic stroke (Vermeer et al., 
2006).  
2.3.4.1. Gender, intermediate hyperglycemia, coronary heart disease and stroke  
 
Several studies have examined the gender-related risk on CHD and stroke in diabetic 
individuals (Kanaya et al., 2002; Lehto et al., 1996; Tuomilehto et al. 1996; Hart et al., 2000; 
Oba et al., 2008; Juutilainen et al., 2004; Hu et al., 2005b; Huxley et al., 2006). However, data 
on gender related risk on CHD and stroke in individuals with hyperglycemia without diabetes 
is scarce. The Chicago Heart Association Detection Project in Industry including 19 502 men 
and 7 251 women, examined the association between 1-h postload plasma glucose levels at 
baseline and 22-year CHD mortality in different age groups. The study found a clear 
relationship between increased risk of CHD and elevated glucose levels in both genders. The 
multivariate adjusted RR were 1.07 (95% CI 1.01-1.14) and 1.03 (0.93-1.13) in men and 1.14 
(1.01-1.28) and 1.18 (1.03-1.34) in women aged 40-59 and 60-74 years, respectively (Orencia 
et al. 1997). The Asia Pacific Cohort Study collaboration, including 237 468 participants, 
found a 23% decreased risk of of ischemic heart disease for each 1 mmol/l reduction in 
fasting glucose levels in individuals without diabetes in women and men across all age groups 
(Lawes et al., 2004). The DECODE Study (2001) including 15 388  men and 7 126 women, 
aged 30-89 years, from 10 European cohorts, found IGT to increase CHD risk in men, but not 
in women. IFG was not found to predict CHD mortality in neither gender. The multivariate 
adjusted (age, study, total cholesterol, BMI, SBP, smoking) HRs were 1.05 (95% CI 0.80-
1.37) and 1.29 (1.02-1.64) in men and 1.25 (0.39-4.03) and 1.22 (0.69-2.15) in women for 
FPG and 2-h PG, respectively. The median follow-up length for the study was 8.8 years (The 
DECODE Study Group, 2001).  
Few studies have examined the gender difference in risk of stroke related to hyperglycemia in 
individuals without diabetes. The Chicago Heart Association Detection Project in Industry 
examined the association with 1- hour postload plasma glucose levels and the risk of stroke in 
19 502 men and 7 251 women. The study found a significant association between elevated 
glucose levels and stroke mortality in men only. The multivariate adjusted (age, race, 
education, SBP, smoking, serum cholesterol, BMI and ECG abnormalities) hazard ratio were 
1.01 (0.80-1.27) and 1.17 (0.92-1.48) in women and men 1.19 (1.05-1.35) and 1.23 (1.02-
1.49) aged 40 to 59 and 60 to 74, respectively. The study had a 22 -year follow-up (Orencia et 
al., 1997). In contrast, the Renfrew/Paisley study,  including 7 052 men and 8 354 women, 
aged 45 to 64 years, found elevated (top 5%) nonfasting blood glucose levels to be associated 
with 20-year stroke mortality in nondiabetic women [OR 2.17 (95% CI 1.44-3.25)], but not in 
nondiabetic men [1.39 (0.79-2.42)]. The analysis were adjusted for age, SBP, DBP, smoking, 
adjusted forced expiratory volume in 1 second, cardiothoracic ratio, height, BMI, diabetes and 
preexisting CHD (Hart et al., 1999).  
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Table 3. Relative risk (95% CI) of coronary heart disease (CHD) and stroke in relation to increase in glucose levels (mmol/L) or as 
indicated. 
 
Study  Follow-
up (yrs) 
Glucose 
definition 
Population, 
age (yrs) 
CHD 
mortality/event 
Overall stroke 
incidence  
/mortality 
Ischemic 
stroke 
incidence 
/mortality 
Hemorrhagic  
stroke 
incidence 
/mortality 
Reference  
The 
Honolulu 
Heart 
Program  
22 non-fasting 
glucose           
1-hour after   
a 50-g load, 
high normal 
compared 
with low 
normal    
7 549 men,      
age 45 to 68  
 
 
 
 
 
 1.43 (1.00-2.04) 0.96 (0.51-1.82) Burchfiel 
et al.,1994 
The British 
Regional 
Heart Study  
9.5 non-fasting 
blood glucose, 
upper quintile 
compared 
with all the 
lower 
quintiles          
7 735  men,   
age 40 to 59 
1.5 (1.1-2.6) 
 
 
 
 
   Perry       
et al.,1994 
Oslo Study  18 non-fasting 
serum glucose 
16 209 men,   
age 40 to 49  
 
 
 
 
1.02 (0.83-1.26)   Håheim  
et al.,1995 
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Chicago 
Heart 
Association 
Detection 
Project in 
Industry 
22 1-hour 
postload 
plasma 
glucose, 
40mg/dl 
increase 
10 269 men, 
age 18 to 39  
6 319 women    
7 993 men,        
age 40 to 59  
932  women         
1 240  men,        
age 60 to 74  
 
age 18 to 39  
men             
1.06 (0.91-1.24)        
age  40 to 59   
women        
1.14 (1.01-1.28) 
men              
1.07 (1.01-1.14)  
age 60 to 74 
women        
1.18 (1.03-1.34)      
men              
1.03 (0.93-1.13)  
 
             
age  40 to 59   
women        
1.01 (0.80-1.27) 
men             
1.19 (1.05-1.35) 
age 60 to 74 
women         
1.17 (0.92-1.48) 
men             
1.23 (1.02-1.49)  
 
     
  Orencia  
et al.,1997 
Whitehall 
Study, the 
Paris 
Prospective 
study and the 
Helsinki 
Policemen 
Study  
20   fasting plasma 
glucose,       
2-h postload 
plasma 
glucose,      
the top 2.5 % 
of glucose 
level 
17 285 men, 
age 45 to 55   
1.34 (1.00-1.80)   
 
 
 
 
  Balkau    
et al.,1998 
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NHANES 
III, Third 
National 
Health and 
Nutrition 
Examination 
Survey 
 fasting plasma 
glucose,          
2-h postload 
plasma 
glucose, 
impaired 
glucose 
tolerance 
compared 
with normal 
glucose 
tolerance  
6 547 
individuals, 
age 40 to 74  
Odds ratio     
1.1 (0.7 -1.6) 
 
 
 
 
 
 Odds ratio     
0.9 (0.5-1.6) 
 Qureshi  
et al.,1998 
Renfrew/   
Paisley 
general 
population 
study 
 
20 non-fasting 
blood glucose,   
the top 5% 
compared 
with the rest 
8 353 women      
7 058 men,        
age 45 to 64  
women        
3.98 (2.29-6.91) 
men             
2.89 (1.49-5.62) 
  Hart et al., 
1999 
Honolulu 
Heart 
Program  
23 non-fasting 
state 1 h after 
a 50-g glucose 
load, 
asymptomatic 
hyperglycemi
a compared 
with low 
normal  
8 006 
Japanese- 
American 
men,            
age 45-68  
2.01 (1.44-2.81) 
 
 
 
 
 
   Rodriguez 
et al.,1999 
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The 
DECODE 
study  
8.8 fasting plasma 
glucose,           
2-h plasma 
glucose 
7 126 women 
15 388 men,        
age 30 to 89  
FPG:       
women        
1.25 (0.39-4.03) 
men             
1.05 (0.80-1.37) 
2-h PG:   
women        
1.22 (0.69-2.15) 
men              
1.29 (1.02-1.64) 
 
 
FPG:       
women         
3.02 (1.11-8.21) 
men             
0.89 (0.57-1.38)     
2-h PG:        
1.21 (0.56-2.59) 
men             
1.26 (0.84-1.88) 
  The 
DECODE 
Study 
Group, 
2001 
The Turku 
Elderly Study 
9.6  
(mean) 
2-h plasma 
glucose, 
impaired 
glucose 
tolerance 
1 032 
individuals,   
age 70  
 
 
 
 
1.47 (0.83-2.61)   Kaarisalo 
et al.,2006 
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3  AIMS OF THE STUDY  
 
1.  To compare the fasting plasma glucose and 2-h plasma glucose criteria with regard to their 
     relation to stroke mortality in European women and men (Article I).  
 
2.  To compare between fasting and 2-h plasma glucose criteria in their relation to incidence of 
      ischemic and hemorrhagic stroke (Article II). 
 
3.  To study the age-and gender-difference in incidence of coronary heart disease and ischemic    
stroke and to estimate to what extent the known cardiovascular risk factors have attributed 
to the difference (Article III).                                                                                                   
 
4. To assess age- and gender-difference in the diabetes-related risk of coronary heart disease        
and ischemic stroke (Article IV).  
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4 POPULATIONS AND METHODS  
4.1. Study population  
The Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe 
(DECODE) was first undertaken on the initiative of the European Diabetes Epidemiology 
Study Group in 1997 with the aim to evaluate the new diagnostic criteria for diabetes proposed 
by the American Diabetes Association in 1997. Researchers in Europe who had done 
population-based or large occupational studies on the prevalence of diabetes mellitus applying 
standard 2-hour 75g oral glucose tolerance tests were invited to participate. The study consists 
of 31 European cohorts from 14 European countries (Cyprus, Denmark, Finland, France, 
Iceland, Israel, Italy, Malta, the Netherlands, Poland, Spain, Sweden, Turkey, United 
Kingdom).   All the individuals included in the study had FPG and 2-h PG (after 75 g of 
glucose load) values at baseline, and most of the cohorts were followed up with regard to the 
mortality and morbidity. Individual data from different participating European cohorts were 
sent to the Diabetes Prevention Unit, Department of Chronic Disease Prevention, National 
Institute for Health and Welfare, in Helsinki, Finland for data analyses. Each study had been 
approved  by  the  local  Ethics  Committees  and  the  Ethics  Committee  of  the  National  Institute  
for Health and Welfare approved the data analysis plan.  This is a sub-data analysis of the 
DECODE study including 25 181 individuals, 11 844 (47%) men and 13 345 (53%) women, 
from 14 European cohorts. The characteristics of subjects are shown in Table 4. 
4.1.1. Study population in articles I-IV  
 
Article I The study population comprised of 21 706 individuals, 11 844 men and 9 862 women, 
aged 25 to 90 years, from 13 European DECODE cohorts. The maximum length of follow-up 
ranged from 3.8 to 27.9 years among different cohorts. Measurements for fasting plasma glucose 
and 75g 2-h oral glucose tolerance test, BMI, total serum cholesterol, systolic and diastolic 
blood pressure, antihypertensive treatment, and smoking status were available for all individuals 
included in the study. 
Article II Only subjects without a history of CVD were included in the study. The study 
population comprised of 18 360 individuals, 9 985 men and 8 375 women, aged 25 to 90 years, 
from 9 DECODE cohorts from Finland and Sweden. The maximum length of follow-up ranged 
from 3.8 to 27.9 years among different cohorts. Measurements for fasting plasma glucose and 
75g 2-h oral glucose tolerance test, BMI, total serum cholesterol, systolic and diastolic blood 
pressure, antihypertensive treatment, and smoking status were available for all individuals 
included in the study. 
Articles III-IV Only subjects without a history of CVD were included in the study. The study 
population comprised of 9 278 participants, 5 111 women and 4 167 men, aged 40 to 69 years, 
from 7 cohorts from Finland and Sweden. The maximum length of follow-up ranged from 4.9  
to 20.6 years in women and in men. A total of 384 (7.5%) women and 442 (10.6%) men had 
diabetes (both diagnosed and undiagnosed). Measurements for fasting plasma glucose and 75g 
2-h oral glucose tolerance test, BMI, total serum cholesterol, HDL-cholesterol, systolic and 
diastolic blood pressure, antihypertensive treatment, and smoking status were available for all 
individuals included in the study. 
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Table 4. Charasteristics of the study population at baseline according to study cohort.  
Data are given as means (standard deviation) adjusted for age, study and sex, or as number (%) as noted 
† The study includes only men
 Men, 
(No) 
Women, 
(No) 
Age 
 
Body 
mass 
index 
(Kg/m2) 
Cholesterol 
(mmol/L) 
Systolic 
blood 
pressure 
(mmHg) 
Diastolic 
blood 
pressure 
(mmHg) 
Fasting  
plasma 
glucose 
(mmol/l) 
2-h 
plasma 
glucose 
(mmol/l) 
Known 
DM,  
No (%) 
Smoking, 
No (%) 
Finland,  
East-West† 
405   76.2 (4.5) 
 
26.4 (3.8) 5.74 (1.13) 157 (22) 85 (11) 5.7 (0.8) 7.5 (2.6) 51 (12.6) 56 (13.8 
FINRISK-
1987 
 1261       1440 54.0 (5.8) 
 
27.8 (4.3) 6.44 (1.23) 148 (21) 88 (11) 5.2 (0.7) 6.3 (2.0) 89 (3.3) 510 (18.9) 
FINRISK-
1992 
877       1041 54.1 (6.0)     
  
27.5 (4.3) 5.96 (1.05) 144 (20) 86 (12) 5.5 (0.8) 6.2 (2.2) 69 (3.6) 390 (20.3) 
FINRISK-
2002  
1786        2055 57.9 (7.8) 
 
27.9 (4.6) 5.78 (1.03) 144 (21) 82 (11) 5.8 (0.9) 6.8 (2.6) 267 (7.0) 1083 (28.2) 
Helsinki 
Policemen 
Study†        
1136   44.7 (8.0)     
  
 
25.7 (2.8) 6.14 (1.24) 138 (18) 83 (11) 6.0 (0.7) 5.5 (1.6) 16 (1.4) 552 (48.6) 
Vantaa  271        335 65.2 (0.4)     
 
27.2 (4.3) 6.06 (1.08) 151 (20) 87 (10) 5.5 (0.7) 7.5 (2.0) 58 (9.6) 101 (16.7) 
Italy, 
Cremona 
799        1003 58.4 (10.8)   
 
26.6 (4.4) 6.12 (1.13) 145 (21) 80 (12) 5.1 (0.8) 5.6 (2.3) 140 (7.8) 399 (22.1) 
Malmö 
Preventive 
Project 
        3483  54.8 (2.4) 25.6 (4.5) 6.13 (1.08) 127 (17) 82 (9) 6.1 (0.9) 8.7 (2.2) 3469 (14) 1002 (28.8) 
The 
Netherlands,  
Hoorn Study  
 1087        1282 61.7 (7.3)    
 
 
26.6 (3.6) 6.66 (1.18) 135 (20) 82 (10) 5.6 (1.0) 6.0 (2.9) 81 (3.4) 790 (33.3) 
Zuthpen 
Study† 
479   75.8 (4.5)  
 
25.6 (3.1) 6.09 (1.10) 150 (22) 82 (12) 5.8 (1.0) 6.5 (3.0) 37 (7.7) 109 (22.8) 
Sweden, 
MONICA 
1733        1760 48.9 (13.4) 
 
26.1 (4.3) 6.05 (1.29) 129 (20) 80 (11) 5.2 (0.7) 5.7 (2.9) 304 (8.7) 654 (18.7) 
Uppsala†  1164   71.0 (0.6) 
 
26.3 (3.4) 5.82 (0.99) 147 (19) 84 (9) 5.5 (0.9) 7.6 (2.9) 67 (5.8) 243 (20.9) 
U.K., 
Goodinge 
448        570 54.6 (10.3) 25.8 (4.8) 6.45 (1.31) 119 (21) 70 (12) 6.1 (0.9) 6.3 (2.2)  385 (37.8) 
Newcastle    
398  
      376 54.8 (12.5) 26.4 (4.5) 5.84 (1.15) 131 (23) 75 (13) 5.9 (1.1) 6.5 (2.6) 17 (2.2) 216 (27.9) 
 43 
4.2. Methods  
4.2.1. Baseline measurements  
 
From each participating study crude data on, date of baseline examination, gender, age, height, 
weight, status of known diabetes and information on how diabetes was assessed, time of day of 
blood sampling, blood sampling used (venous whole blood, venous plasma, capillary whole 
blood), glucose load; FPG (mmol/L) ?10 hours fasting time ,  and 2-h PG (mmol/L) 2-h after 
75-g glucose load, total serum cholesterol (mmol/L), SBP (mmHg) and DBP (mmHg), 
antihypertensive treatment, and smoking status were collected and the details are shown in 
Appendix 1., Appendix 2. and Appendix 3. Vital status and the cause of death were recorded 
for participants in all of the studies. Participants who had emigrated and whose vital status 
could not be confirmed were treated as censored cases. 
4.2.2. Definitions  
Diabetes and intermediate hyperglycemia 
 
Individuals with history of diabetes were classified with known diabetes. Individuals who had 
not been diagnosed previously with diabetes were classified according to either 2-h PG criteria 
?11.1 mmol/L for newly diagnosed diabetes, 7.8-11.0 mmol/L for IGT, and <7.8 mmol/L for 
normal glucose tolerance (NGT)) or FPG criteria ?7.0 mmol/L for newly diagnosed diabetes, 
6.1-6.9 mmol/L for IFG,   and <6.1 mmol/L for normal fasting glucose (NFG) (World Health 
Organization and International Diabetes Federation, 2006) criteria.  IFG and IGT refer to 
states of intermediate hyperglycemia.  
Cardiovascular disease events 
 
The fatal and nonfatal events of CHD and cerebrovascular diseases were coded according to 
the International Classification of Diseases (8th, 9th revisions and 10th revision). The nonfatal 
CHD events were classified with codes 410-411 (ICD-9) and I21-I22, I24 (ICD-10) and fatal 
events with codes 410-414 (ICD-9) and I20-I25 (ICD-10). Fatal events of cerebrovascular 
diseases were coded with 430-439 (ICD-8 and ICD-9) and I60-I69 (ICD-10). Nonfatal and 
fatal events for overall stroke were classified with codes 430-431, 433-434, 436 (ICD-9) and 
I60-I61, I63-I64 (ICD-10) and the nonfatal and fatal events for subtypes of stroke with codes 
433-434 (ICD-9) and I63 (ICD-10) for ischemic stroke, with codes 430-431 (ICD-9) and I 60-
I61 (ICD-10) for hemorrhagic stroke and with codes 436 (ICD-9) and I64 (ICD-10) for 
unspecified stroke. In the Finnish and Swedish cohorts the information on CVD mortality and 
morbidity were collected from National Causes of Death Register and the National Hospital 
Discharge Registry and ascertained by using a computerized record linkage of individual ID 
numbers of each of the individuals participating in the study. 
Other measurments  
The  BMI  was  calculated  as  weight  in  kilograms  divided  by  the  square  of  height  in  meters,  
mean arterial pressure (MAP) was defined as [(2 x diastolic)+systolic] / 3). Individuals were 
classified with hypertension if SBP ?140 and/or DBP ? 90 mmHg and/or they had 
hypertension treatment. Smoking status was defined as non-smoker, ex-smoker or current 
smoker.  
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4.2.3. Statistical Methods  
 
The data analysis was carried out by using SPSS for Windows version 15.0. Cox proportional 
hazards model was used to estimate the assocation between risk factors with the end points.  
The analysis was adjusted for age, center, MAP or hypertension status, BMI, total serum 
cholesterol, HDL-cholesterol, smoking status and sex. General linear model of the univariate 
analysis of variance was used to estimate the means. Chi-squared log-likelihood ratio test 
were used to evaluate whether the two glucose criteria differ in their prediction of the new 
events of stroke. Univariate analysis of variance was used to estimate the trend in 
cardiovascular risk factors with aging. A p-value <0.05 (two-tailed) was considered 
statistically significant.  
 
The equations for transformation of glucose concentration was done based on 294 paired 
blood samples of whole (capillary and serum) blood and plasma glucose concentration drawn 
from a standard 75 g oral glucose tolerance test in 74 subjects at 0, 30, 60 and 120 minutes at 
at the Diabetes Prevention Unit, Department of Chronic Disease Prevention, National Institute  
for Health and Welfare, Helsinki Finland.   A mixed model with random effects of individual 
and sample was used to evaluate the relationship between glucose concentrations measured by 
different measures (Carstensen et al., 2008).  
 
 
The transformation of glucose concentration: 
 
- plasma glucose (mmol/l) =0.558+1.119 * whole blood glucose (mmol/l) 
- plasma glucose (mmol/l) =0.102+1.066 * capillary blood glucose (mmol/l)  
- plasma glucose (mmol/l) =-0.137+1.047 * serum glucose (mmol/l)  
 
5 RESULTS 
5.1. Hyperglycemia and stroke incidence and mortality  
      - fasting versus 2-hour glucose criteria (Article I, II) 
5.1.1. Charasteristics of paricipants  
 
Baseline characteristics of subjects (Article I, II) are shown in Table 5. Both women and 
men with diagnosed and undiagnosed diabetes were older and had higher BMI compared to 
individuals without diabetes.  
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Table 5. Baseline characteristics and multivariate adjusted hazard ratios (95 % confidence intervals) for death from stroke for subjects 
according to fasting (FPG) and 2-hour plasma (2-h PG) glucose categories.  
 
                         FPG (mmol/L)                        2-h PG (mmol/L) Known DM 
    < 6.1   6.1-6.9 ? 7.0    < 7.8      7.8-11.0 ??11.1  
Men            
No. (%) 8540 (72.1) 2043 (17.2) 537 (4.5) 9065 (76.5) 1558 (13.2) 497 (4.2) 724 (6.1) 
Age 56.9 (0.1) 57.2 (0.3) 62.4 (0.5) 55.8 (0.1) 63.2 (0.3) 65.1 (0.5) 62.8 (0.4) 
Body mass index 
(Kg/m2) 
26.3 (0.0) 27.4 (0.1) 29.0 (0.2) 26.3 (0.0) 27.7 (0.1) 28.9 (0.2) 28.3 (0.1) 
Cholesterol (mmol/L) 6.04 (0.01) 6.09 (0.03) 6.11 (0.05) 6.07 (0.01) 5.99 (0.03) 6.04 (0.05) 5.78 (0.04) 
Systolic blood 
pressure (mmHg) 
140 (0.2) 145 (0.4) 148 (0.9) 140 (0.2) 147 (0.5) 151 (0.9) 145 (0.7) 
Diastolic blood 
pressure (mmHg) 
83 (0.1) 85 (0.3) 87 (0.5) 83 (0.1) 86 (0.3) 87 (0.5) 84 (0.4) 
Smoking, No (%) 2507 (29.4) 637 (31.2) 157 (29.2) 2835 (31.3) 360 (23.1) 106 (21.3) 166 (22.9) 
Stroke        
No (%) 141 (1.7) 45 (2.2) 15 (2.8) 153 (1.7) 35 (2.2) 13 (2.6) 30 (4.1) 
No/1000 Person-
years 
1.46 1.90 3.24 1.43 2.47 3.50 5.57 
Women         
No. (%) 8169 (82.8) 969 (9.8) 252 (2.6) 7766 (78.7) 1281 (13.0) 343 (3.5) 472 (4.8) 
Age 54.9 (0.1) 59.0 (0.3) 61.1 (0.6) 54.5 (0.1) 59.6 (0.3) 62.4 (0.5) 60.8 (0.5) 
Body mass index 
(Kg/m2)  
26.5 (0.1) 28.6 (0.2) 30.6 (0.3) 26.4 (0.1) 28.6 (0.1) 30.0 (0.3) 30.1 (0.2) 
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Cholesterol (mmol/L)  6.22 (0.01) 6.27 (0.04) 6.32 (0.07) 6.22 (0.01) 6.27 (0.03) 6.21 (0.06) 5.86 (0.05) 
Systolic blood 
Pressure (mmHg)  
137 (0.2) 141 (0.7) 143 (1.3) 137 (0.2) 144 (0.6) 147(1.1) 147(1.0) 
Diastolic blood 
pressure (mmHg) 
80 (0.1) 81 (0.4) 82 (0.7) 80 (0.1) 83 (0.3) 84 (0.6) 81 (0.5) 
Smoking, No (%) 1650 (20.2) 237 (24.5) 67 (26.6) 1712 (22.0) 184 (14.4) 58 (16.9) 67 (14.2) 
Stroke        
No (%) 37 (0.5) 10 (1.0) 7 (2.8) 36 (0.5) 9 (0.7) 9 (2.6) 14 (3.0) 
No/1000 Person-
years 
0.44 1.25 3.35 0.46 0.72 3.03 3.93 
  Data are given as means (standard error) adjusted for age, and study or as number (%) as noted. 
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5.1.2. Hyperglycemia and stroke mortality (Article I) 
 
Diagnosed diabetes increased stroke mortality in both genders. The multivariate-adjusted 
hazard ratio (adjusted for age, study, hypertension status, total cholesterol, BMI and 
smoking)  for fatal stroke events was highest in men and women with screen detected 
diabetes defined by either FPG or 2-h PG criteria as compared with men and women with 
normal or impaired glucose values. The cumulative hazard ratios for stroke mortality were 
highest in individuals with diagnosed diabetes and screened diabetes defined by either 
glucose criteria (Figure 2a-2d); in women the risk was slightly increased for IFG (Figure 
2b) and in men for IGT (Figure 2c). The stroke mortality risk was lowest in women with 
NGT or IGT (Figure 2d) and in men with NFG or IFG (Figure 2a).  
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Figure 2. Cumulative stroke mortality curves derived from Cox regression analysis for 
FPG (mmol/l) and 2-h PG category and for people with prior history of diabetes (known 
DM) in men (Figure 2a-2c)  and  in  women (Figure 2b-2d). The analysis is adjusted for 
age, study, BMI, total cholesterol, smoking and hypertension status.  
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The hazard ratios corresponding to 1 SD increase in 2-h PG were a better predictor of a fatal 
stroke event than those in FPG in men [1.21 (1.06-1.38)] vs 1.04 (0.85-1.27)], whereas FPG 
was better than 2-h PG in women [1.31 (1.07-1.61) vs 1.54 (1.26-1.90)], after adjusting for age, 
study,  BMI  and  total  cholesterol.   Addition  of  2-h  PG  to  the  model  with  FPG  significantly  
improved prediction of stroke mortality in men (Chi square = 10.12, p = 0.001) but not in 
women (Chi square = 0.01, p = 0.94), whereas addition of FPG with 2-h PG improved stroke 
mortality in women (Chi square = 4.08, p = 0.04), but not in men (Chi square = 3.29, p = 0.07). 
The interaction between gender and stroke mortality was statistically significant for FPG 
(p=0.05), but not for 2-h PG (p= 0.53) levels.  
5.1.3. Hyperglycemia and the incidence of ischemic and hemorrhagic stroke (Article II)  
 
Both FPG and 2-h PG predicted the risk of ischemic and overall stroke, but not hemorrhagic 
stroke subtype. The multivariate-adjusted hazard ratios corresponding to a 1 SD increase for 
ischemic stroke were 1.12 (1.02-1.22) and 1.14 (1.05-1.24) and for hemorrhagic stroke 1.07 
(0.88-1.30) and 1.06 (0.90-1.27) for FPG and 2-h PG, respectively after adjustment for age, 
study, BMI, total cholesterol, smoking, MAP and sex. Adding 2-h PG to the model with FPG 
significantly improved the prediction of stroke incidence of all stroke subtypes (??  = 4.93, 
p=0.03) and for ischemic stroke (??  =5.45, p=0.02) whereas adding FPG to the model with 2-h 
PG did not improve the prediction of stroke incidence neither for all stroke subtypes (??  =0.79, 
p=0.37) nor for ischemic stroke (??  = 0.02, p=0.88). The linear form of the FPG and 2-h PG did 
not predict the incidence of hemorrhagic stroke (Table  6).  We  also  performed  a  sensitivity  
analysis in which the length of follow-up was truncated at 15 years. The present findings were 
in accordance with the results we obtained from the sensitivity analysis. The hazard ratios for 
FPG (Figure 3a) and 2-h PG (Figure 3b) for each study cohort and for all cohorts combined 
based on the meta-analysis showed no large variation in between the study cohorts with regard 
to the relationship between hyperglycemia and stroke incidence (Data not published).  
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Table 6. Hazard ratios (95 % confidence intervals) for the incidence of overall and subtypes of stroke corresponding to a 1SD increase in fasting 
(FPG) and 2-hour plasma glucose (2-h PG) levels (mmol/L). The ?? indicates the changes in the model prediction when the variable indicated 
was removed from the model with both FPG and 2-h PG simultaneously.  Subjects with previously diagnosed diabetes are excluded.  
 
1 SD is 1.2 for FPG and 2.7 for 2-h PG. 
Adjusted for age, study, BMI, total cholesterol, smoking, MAP and sex
                                                                             Stroke incidence 
                 
Ischemic                                 Hemorrhagic                       Unspecified                           All-causes 
Total  n= 690                            n= 180                n= 38 n= 908                      
FPG  1.07 (0.98-1.17) 0.96 (0.78-1.17) 1.32 (1.04-1.68) 1.12 (1.04-1.21) 
2h PG  1.12 (1.04-1.22) 0.97 (0.81-1.15) 1.36 (1.00-1.83) 1.14 (1.06-1.22) 
?? for FPG, 1 df (p)         0.02 (0.88) 0.08 (0.78) 1.27 (0.26) 0.79 (0.37) 
??  for 2-h PG, 1 df (p)                     5.45 (0.02) 0.06 (0.82) 1.11 (0.29) 4.93 (0.03) 
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a                                         Fasting plasma glucose  
      
-2 -1 0 1 2
Beta coefficient (95% CI) per 1SD of FPG
Overall HR 1.17 (1.08-1.28)
Finland, East-West* 
Finnrisk-1987
Finnrisk-1992
Finnrisk, 2002 
Helsinki Policemen Study*
Vantaa* 
Sweden-MONICA
Uppsala 
Malmö Preventive 
Project#
 
 
b                                         2-h plasma glucose  
 
      
-2 -1 0 1 2
Beta coefficient (95% CI) per 1SD of 2-h PG
Overall HR 1.16 (1.06-1.26)
Finland, East-West* 
Finnrisk-1987
Finnrisk-1992
Finnrisk, 2002 
Helsinki Policemen Study*
Vantaa 
Sweden-MONICA
Uppsala* 
Malmö Preventive 
Project#
 
 
Figure 3. Individual and overall ?- coefficients (?) and 95 % confidence intervals (?) 
corresponding to a 1 SD increase in FPG (Figure 3a) and 2-h PG levels (Figure 3b) for 
ischemic  stroke  incidence.  The  analysis  was  adjusted  for  age,  study,  BMI,  total  cholesterol,  
MAP and smoking.  
*Study includes only men, #Study includes only women 
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5.2. The impact of gender and age on CHD and stroke incidence (Article III-IV) 
5.2.1. Charasteristics of participants 
The baseline charasteristics of subjects according to age group and gender are shown in     
Table  7. Mean BMI and total cholesterol levels were higher in men than in women in the 
youngest age group (40-49 years), and similar in age group 50-59 years and tended to be lower 
in men than in women in age group 60-69 years. HDL was higher in women than in men in all 
age groups. Hypertension was more common in young men than in young women, but the 
difference leveled off in the oldest age group. The number of individuals with diabetes 
increased in both genders with increasing age and was higher in men compared with women. 
Smoking was less common in women than in men. The increase in trend between age groups 
for the prevalence of hypertension and diabetes was significant (p=0.001) in both genders. 
More women and men were smokers in the age group 40-49 years compared with the age 
groups 50-59 and 60-69 years.  
 
In  the  non-diabetic  population,  the  means  of  BMI  and  total  cholesterol  as  well  as  the  
prevalence of hypertension were all higher in men than in women in the age group 40-49 years, 
but the gender differences leveled off with increasing age and became even or lower in men 
than in women in the age group 60-69 years. In non-diabetic women and men the increasing 
trend with aging was significant (p=0.001) for BMI, cholesterol and hypertension. Diabetic 
women were, however, more obese than diabetic men in all ages. HDL-cholesterol was higher 
in women than in men and smoking was more common in men than in women in all ages 
regardless of the diabetic status. The increasing trend in known CVD risk factors with aging in 
diabetic individuals was significant only for total cholesterol levels in women (Table 8).  
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Table 7. The baseline cahrasteristics of subjects according to age group and gender.
                            Mean (SD)                                                                            No, (%)                                             
Age groups 
 (yr) 
No, (%) BMI  
(Kg/m2) 
Cholesterol 
(mmol/L) 
 HDL  
(mmol/L) 
Hypertension 
 
    DM  
 
Smoker  
 
CHD  
 
Ischemic stroke  
 
40-49          
Women  1380 (55.1) 26.1 (0.1) 5.70 (0.03) 1.56 (0.01) 575 (41.7) 64 (4.6) 336 (24.3) 24 (1.7)        14 (1.0) 
Men  1125 (44.9) 26.9 (0.1) 6.18 (0.03) 1.28 (0.01) 600 (53.3) 65 (5.8) 350 (31.1) 54 (4.8)        19 (1.7) 
p-value  <0.001 <0.001 <0.001 <0.001 0.199 <0.001 <0.001        0.141 
50-59          
Women  2227 (54.8) 27.6 (0.1) 6.22 (0.02) 1.61 (0.01) 1387 (62.3) 147 (6.6) 406 (18.2) 69 (3.1)        47 (2.1) 
Men  1837 (45.2) 27.7 (0.1) 6.15 (0.03) 1.30 (0.01) 1247 (67.9) 195 (10.6) 550 (29.9)  155 (8.4)        57 (3.1) 
p-value  0.396 0.033 <0.001 <0.001 <0.001 <0.001 <0.001        0.046 
60-69          
Women  1504 (55.5) 28.1 (0.1) 6.44 (0.03) 1.54 (0.01) 1138 (75.7) 173 (11.5) 200 (13.3) 89 (5.9)        68 (4.5) 
Men  1205 (44.5) 27.4 (0.1) 6.01 (0.03) 1.28 (0.01) 920 (76.3) 182 (15.1) 280 (23.2) 139 
(11.5) 
       61 (5.1) 
p-value  <0.001 <0.001 <0.001 0.679 0.006 <0.001 <0.001        0.511 
Total           
Women 5111 (55.1) 27.3 (0.1) 6.15 (0.02) 1.58 (0.01) 3100 (60.7) 384 (7.5) 942 (18.4) 182 (3.6)        129 (2.5) 
Men  4167 (44.9) 27.4 (0.1) 6.12 (0.02) 1.29 (0.01) 2767 (66.4) 442 (10.6) 1180 (28.3) 348 (8.4)        137 (3.3) 
p-value  0.299 0.270 <0.001 <0.001 <0.001 <0.001 <0.001        0.028 
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Table 8. Baseline characteristics and the incidence of cardiovascular end points in women and men according to age groups and diabetic status.  
 
                                                         Age Groups, years   
                  40-49                    50-59                     60-69  
Non-diabetic Women  Men  p-value  Women  Men  p-value Women  Men  p-value 
No, (%) 1316 (95.4) 1060 (94.2)  2080 (93.4) 1642 (89.4)  1331 (88.5) 1023 (84.9)  
BMI (Kg/m2) 25.87 (0.12) 26.75 (0.11) <0.001 27.28 (0.10) 27.45 (0.09) 0.226 27.78 (0.13) 27.11 (0.11) <0.001 
Cholesterol (mmol/L) 5.69 (0.03) 6.18 (0.03) <0.001 6.23 (0.03) 6.18 (0.03) 0.072 6.44 (0.03) 6.02 (0.03) <0.001 
HDL (mmol/L) 1.57 (0.01) 1.29 (0.01) <0.001 1.62 (0.01) 1.31 (0.01) <0.001 1.57 (0.01) 1.28 (0.01) <0.001 
Hypertension (Yes/No) 537 (40.8) 551 (52.0) <0.001 1270 (61.1) 1085 (66.1) 0.002 988 (74.2) 766 (74.9) 0.721 
Smoking vs. non-smoking 316 (24.0) 322 (30.4) <0.001 374 (18.0) 488 (29.7) <0.001 177 (13.3) 240 (23.5) <0.001 
CHD  20 (1.5) 47 (4.4) <0.001 57 (2.7) 132 (8.0) <0.001 68 (5.1) 114 (11.1) <0.001 
Ischemic stroke  12 (0.9) 16 (1.5) 0.180 43 (2.1) 48 (2.9) 0.093 52 (3.9) 44 (4.3) 0.632 
Diabetic          
No, (%) 64 (4.6) 65 (5.8)  147 (6.6) 195 (10.6)  173 (11.5) 182 (15.1)  
BMI (Kg/m2) 30.51 (0.83) 29.85 (0.65) 0.584 31.86 (0.48) 29.74 (0.31) <0.001 30.41 (0.39) 29.25 (0.31) 0.017 
Cholesterol (mmol/L) 5.88 (0.12) 6.24 (0.15) 0.077 6.11 (0.09) 5.94 (0.10) 0.417 6.43 (0.09) 5.95 (0.09) 0.007 
HDL (mmol/L) 1.46 (0.06) 1.20 (0.05) <0.001 1.41 (0.03) 1.24 (0.03) <0.001 1.34 (0.03) 1.23 (0.02) <0.001 
Hypertension (Yes/No) 38 (59.4) 49 (75.4) 0.052 117 (79.6) 162 (83.1) 0.410 150 (86.7) 154 (84.6) 0.575 
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Data are given as means (standard error) adjusted for age, study and sex, or as number (%). 
p-values reflect differences between men and women.  
 
 
 
Smoking vs. non-smoking 20 (31.3) 28 (43.1) 0.117 32 (21.8) 62 (31.8) <0.001 23 (13.3) 40 (22.0) <0.001 
CHD  4 (6.3) 7 (10.8) 0.358 12 (8.2) 23 (11.8) 0.273 21 (12.1) 25 (13.7) 0.654 
Ischemic stroke  2 (3.1) 3 (4.6) 0.661 4 (2.7) 9 (4.6) 0.364 16 (9.2) 17 (9.3) 0.976 
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5.2.2. The incidence of coronary heart disease and ischemic stroke, and their risk factors  
in relation to age and gender  
 
Men of all ages had higher incidence of acute CHD and ischemic stroke than did women, but 
the difference was more prominent for CHD than for ischemic stroke. Compared with the 
women aged 40-49 years the multivariate adjusted (age, study, hypertension status, BMI, total 
serum  cholesterol,  HDL-cholesterol  and  smoking  status)  hazards  ratios  of  acute  CHD  and  
ischemic stroke increased in older age groups in both genders, and were higher for men than 
for women given the same age. The gender difference in the hazard ratios was, however, 
smaller for ischemic stroke than for CHD (Table 9).  
 
The cumulative hazard ratios increased with increasing age in both genders. The risk for CHD 
incidence was highest in men age group 60-69 years and lowest in women in the age group 40-
49 years. The risk was higher in men than in women in all age groups (Figure 4a). For 
ischemic stroke risk the gender differences smaller than that for CHD, being slightly higher in 
men than in women across age groups (Figure 4b). 
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Table 9. Hazard ratios (HR) and incidence rates per 1000 person-years by 10- year age groups, for coronary heart disease, ischemic stroke. 
Women 40-49 years are used as the reference group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age groups (yr)                       40-49                                                                     50-59                         60-69 
  Women Men     Women   Men         Women             Men  
Coronary heart disease       
No (No/1000 Person-years) 24 (1.26) 54 (3.41) 69 (2.51) 155 (7.10) 89 (5.42) 139 (11.62) 
HR (95% CI) 1 1.82 (1.12-2.97) 1.71 (1.07-2.74) 3.87 (2.49-6.02) 3.49 (2.18-5.57) 7.22 (4.59-11.36) 
Ischemic stroke       
No (No/1000 Person-years) 14 (0.74) 19 (1.20) 47 (1.71) 57 (2.61) 68 (4.14) 61 (5.10) 
HR (95% CI) 1 1.26 (0.62-2.55) 2.17 (1.18-3.97) 2.64 (1.45-4.82) 4.89 (2.67-8.97) 5.19 (2.81-9.58) 
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Figure 5. Cumulative hazards for coronary heart disease (Figure 4a)  and  ischemic  stroke  (Figure 4b) incidence in 10- year age groups in 
women and men. Women aged 40-49 years are used as the reference group. The analysis were adjusted for BMI, total cholesterol, HDL-
cholesterol and status of diabetes mellitus, hypertension and smoking.  
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Ageing increased the risk for ischemic stroke more markedly in women compared with men 
(Table 10).  In addition to ageing, smoking, diabetes and elevated cholesterol levels were all 
risk  predictors  for  CHD  incidence,  but  elevated  blood  pressure  rather  than  cholesterol  levels  
predicted the ischemic stroke incidence (Table 10).  
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Table 10. Hazard ratios for coronary heart disease and ischemic stroke, corresponding to a one SD increase in continuous variables or as 
indicated.  
 
 Coronary heart disease Ischemic stroke  
    Women Men Women Men 
   Age (10 yrs) 2.07 (1.52-2.81) 2.35 (1.92-2.87) 3.36 (2.31-4.88) 2.38 (1.67-3.39) 
   BMI, kg/m2 1.22 (1.05-1.42) 1.06 (0.93-1.19) 1.01 (0.83-1.22) 1.14 (0.94-1.39) 
   2-h PG mmol/l? 1.14 (0.99-1.32) 1.12 (1.00-1.26) 1.03 (0.84-1.25) 1.23 (1.03-1.47) 
   FPG mmol/l? 1.00 (0.80-1.25) 1.19 (1.06-1.34) 1.27 (1.04-1.56) 1.13 (0.90-1.44) 
   Cholesterol, mmol/l 1.20 (1.03-1.39) 1.37 (1.23-1.52) 0.90 (0.75-1.09) 0.96 (0.79-1.16) 
   HDL, mmol/l 0.77 (0.64-0.93) 0.84 (0.74-0.95) 0.81 (0.65-1.01) 0.97 (0.78-1.19) 
   Hypertension (Yes/No) 1.39 (0.94-2.06) 1.19 (0.91-1.56) 2.21 (1.33-3.68) 1.20 (0.75-1.91) 
   Smoking vs. non-smoking 3.10 (2.13-4.50) 1.99 (1.52-2.60) 1.38 (0.80-2.39) 1.89 (1.17-3.06) 
   Diabetes mellitus (Yes/No) ? 2.44 (1.66-3.59) 2.10 (1.55-2.84) 2.24 (1.38-3.64) 2.97 (1.93-4.57) 
?Fitted in three separate model 
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5.2.3. The impact of diabetes on the incidence of coronary heart disease and ischemic 
stroke  
 
The event rates for acute CHD and ischemic stroke were higher in men with and without 
diabetes compared with their female counterparts. The gender difference for CHD was larger in 
the non-diabetic than in the diabetic individuals, whereas this was not as substantial for 
ischemic stroke as for CHD. The multivariate-adjusted hazard ratios of acute CHD events 
increased with aging and diabetes, and were higher in men both with and without diabetes 
compared with age matched women, but the gender difference was diminished in diabetic 
individuals. In contrast, the gender difference with the ischemic stroke was enlarged in the 
diabetic population probably because the risk of ischemic stroke increased more in diabetic 
men than in diabetic women (Table 11). Diabetes and aging were associated with an increased 
risk of acute CHD and ischemic stroke events in both gender, however, diabetes was a stronger 
risk predictor for the risk of ischemic stroke than for CHD. Cholesterol predicted the risk of 
acute CHD, but not ischemic stroke event, in both genders. FPG and 2-h PG levels were CHD 
risk predictors only in men, whereas FPG predicted ischemic stroke risk in women and 2-h PG 
in men only. Hypertension increased the acute ischemic stroke risk, and BMI CHD risk only in 
women (Table 12). 
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Table 11. Event rates per 1000 person-years and hazard ratios (95% confidence intervals) for acute CHD and ischemic stroke events by diabetic  
status (partly unpublished data). 
 
                                                                Non-diabetic                                        Diabetic  
   Age groups, yr   Age groups, yr  
           40-49          50-59         60-69          40-49          50-59         60-69  
CHD        
Rates        
Women  1.09 (0.68-1.65) 2.20 (1.68-2.83) 4.61 (3.61-5.81) 5.68 (1.80-13.69) 7.50 (4.06-12.74) 12.53 (7.96-18.82) 
Men  3.11 (2.31-4.10) 6.57 (5.52-7.77) 10.82 (8.97-12.95) 9.62 (4.21-19.03) 13.24 (8.59-19.55) 17.51 (11.59-25.47) 
HRs Adjustment       
Model 1 Study       
Women  1 2.10 (1.26-3.49) 4.91 (2.97-8.12) 6.09 (2.08-17.82) 7.95 (3.88-16.26) 14.65 (7.87-27.28) 
Men  2.90 (1.72-4.90) 6.43 (4.02-10.29) 12.34 (7.62-19.97) 10.44 (4.41-24.70) 15.98 (8.76-29.15) 22.54 (12.41-40.97) 
Model 2 
 
Model 1+ BMI       
Women  1 1.99 (1.20-3.32) 4.57 (2.76-7.58) 5.07 (1.72-14.92) 6.59 (3.20-13.61) 12.23 (6.52-22.96) 
Men  2.81 (1.67-4.75) 6.13 (3.82-9.81) 11.91 (7.36-19.29) 8.94 (3.76-21.26) 14.26 (7.79-26.09) 19.78 (10.84-36.09) 
Model 3 Model 2 
+hypertension 
      
Women  1 1.91 (1.14-3.18) 4.26 (2.56-7.08) 5.05 (1.71-14.85) 6.19 (3.00-12.78) 11.28 (6.00-21.21) 
Men  2.76 (1.63-4.66) 5.79 (3.61-9.29) 11.04 (6.80-17.93) 8.44 (3.55-20.09) 12.95 (7.05-23.77) 18.08 (9.88-33.10) 
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Model 4 Model 3+ total 
cholesterol, 
HDL-cholesterol 
      
Women  1 1.67 (1.00-2.79) 3.46 (2.07-5.77) 4.54 (1.54-13.36) 5.40 (2.62-11.14) 8.50 (4.50-16.03) 
Men   2.07 (1.22-3.52) 4.35 (2.70-7.03) 8.38 (5.13-13.70) 6.10 (2.55-14.58) 10.14 (5.50-18.70) 14.24 (7.74-26.20) 
Model 5 Model 4+ 
smoking 
      
Women  1 1.78 (1.06-2.97) 3.75 (2.24-6.26) 4.35 (1.48-12.80) 5.49 (2.66-11.33) 8.84 (4.68-16.72) 
Men   1.94 (1.14-3.29) 4.23 (2.61-6.84) 8.40 (5.13-13.76) 5.40 (2.26-12.93) 9.54 (5.17-17.63) 13.76 (7.47-25.34) 
Ischemic 
stroke  
       
Rates        
Women  0.65 (0.35-1.11) 1.66 (1.22-2.22) 3.53 (2.66-4.59) 2.84 (0.48-9.38) 2.50 (0.79-6.03) 9.54 (5.65-15.17) 
Men  1.06 (0.63-1.68) 2.39 (1.78-3.14) 4.18 (3.07-5.56) 4.12 (1.05-11.22) 5.18 (2.53-9.50) 11.91 (7.17-18.68) 
HRs Adjustment       
Model 1 Study       
Women  1 2.62 (1.38-4.97) 5.71 (3.01-10.81) 5.08 (1.14-22.72) 4.23 (1.36-13.12) 17.78 (8.26-38.30) 
Men  1.63 (0.77-3.43) 3.86 (2.05-7.26) 7.15 (3.73-13.69) 7.87 (2.22-27.93) 10.60 (4.46-25.20) 27.22 (12.76-58.10) 
Model 2 
 
Model 1+ BMI       
Women  1 2.54 (1.34-4.83) 5.46 (2.88-10.38) 4.57 (1.02-20.55) 3.78 (1.21-11.83) 16.14 (7.42-35.10) 
Men  1.59 (0.75-3.37) 3.75 (1.99-7.06) 6.99 (3.65-13.39) 7.21 (2.02-25.72) 9.90 (4.15-23.66) 25.23 (11.75-54.19) 
Model 3 Model 2 
+hypertension 
      
Women  1 2.33 (1.23-4.44) 4.80 (2.52-9.14) 4.47 (0.99-20.13) 3.33 (1.06-10.44) 13.81 (6.33-30.15) 
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Men  1.53 (0.72-3.24) 3.37 (1.78-6.36) 6.07 (3.16-11.69) 6.47 (1.81-23.11) 8.28 (3.45-19.85) 21.42 (9.92-46.26) 
Model 4 Model 3+ total 
cholesterol, 
HDL-cholesterol 
      
Women  1 2.39 (1.25-4.56) 4.92 (2.56-9.44) 4.21 (0.94-18.99) 3.28 (1.05-10.28) 13.36 (6.08-29.40) 
Men  1.36 (0.64-2.91) 3.00 (1.57-5.72) 5.37 (2.76-10.44) 5.62 (1.56-20.21) 7.26 (3.01-17.52) 18.93 (8.70-41.19) 
Model 5 Model 4+ 
smoking 
      
Women  1 2.48 (1.30-4.73) 5.17 (2.69-9.94) 4.14 (0.92-18.66) 3.32 (1.06-10.43) 13.91 (6.31-30.66) 
Men   1.26 (0.59-2.70) 2.83 (1.48-5.42) 5.11 (2.62-9.97) 4.91 (1.36-17.74) 6.75 (2.79-16.32) 18.06 (8.29-39.37) 
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Table 12. Hazard ratios (95% confidence intervals) corresponding to a one SD increase in continuous variables or as indicated.  
 CHD Ischemic stroke 
    Women Men Women Men 
   Age, 40-49 yrs 1 1 1 1 
   Age, 50-59  yrs 1.70 (1.06-2.75) 2.16 (1.58-2.95) 2.16 (1.17-3.98) 2.12 (1.26-3.58) 
   Age, 60-69  yrs 3.53 (2.15-5.79) 3.99 (2.85-5.58) 5.49 (2.93-10.28) 3.63 (2.06-6.38) 
   BMI, kg/m2 1.22 (1.06-1.40) 1.02 (0.91-1.14) 0.97 (0.81-1.16) 1.05 (0.88-1.26) 
   Cholesterol, mmol/l 1.25 (1.09-1.43) 1.34 (1.22-1.49) 0.94 (0.79-1.12) 1.00 (0.85-1.19) 
   HDL, mmol/l 0.71 (0.59-0.85) 0.84 (0.74-0.94) 0.79 (0.64-0.97) 0.90 (0.75-1.09) 
   Hypertension (Yes/No) 1.51 (1.03-2.21) 1.27 (0.97-1.65) 2.33 (1.42-3.81) 1.47 (0.94-2.30) 
   Smoking vs. non-smoking 2.81 (1.97-4.01) 1.95 (1.51-2.52) 1.16 (0.67-1.99) 2.06 (1.33-3.19) 
   Diabetes mellitus (Yes/No)  2.48 (1.69-3.65) 2.09 (1.55-2.82) 2.37 (1.46-3.84) 3.01 (1.95-4.64) 
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6 DISCUSSION 
6.1. Study design and methodology  
The strength of the DECODE study was the long-length of follow-up and the collaborative 
data analysis, which gives more statistical power and possibility for a detailed analysis 
between gender and different age groups than if the analysis was performed individually by 
the individual study centres. The current study covers population cohorts from nine 
different European countries. However, different cultural background, which exists in 
between European populations, is associated with many factors such as different living 
conditions and life style factors that may results in differences in risk factor profiles and 
thus CVD outcome in between individual centres. Thus, more studies on the field are 
required.  
 
Even though, the classification of CHD and stroke death from death certificates is not 
perfect, the principle of death certification has been the same for both gender and for all risk 
factor  strata.  The  CHD  and  stroke  mortality  and  incidence  have  also  been  uniformly  
classified with codes of International Classification of Diseases. Furthermore, in Finland 
and Sweden the national death and hospital discharge registers provide complete follow-up 
information for outcomes and the accuracy of the CHD and stroke diagnoses in the Hospital 
Discharge Register and Causes of Death Register when comparing the CHD and stroke 
events to the data provided by the population-based CHD and stroke registers in Finland 
and Sweden has been found to be fairly good. As the individual surveys have been 
conducted independently some variations exists in laboratory measurement methods in 
between the different cohorts. Thus, in order to make up the differences between studies, 
the analysis was adjusted for “cohort”. Also, to take into account the differences in study 
protocols and the laboratory measures between studies, study-and- sex specific SD was 
used to standardize the variables in the collaborative data analysis.   
 
Information on the other known CHD and stroke risk factors such as diet, alcohol use, 
psychosocial factors, physical activity and family history of CVD were not available and 
not taken into account in the present analysis.  
 
The strength of the present study is that all the cohorts used in the study had data available 
for both FPG and 2-h glucose levels.  This is the first study to investigate the question of 
glucose levels and the risk of stroke in a study group where all participants had had a 75g 2-
h oral glucose tolerance test. The collaborative data analysis in the DECODE study 
provides an economic and efficient use of excisting population-based databases.  
6.2. Interpretation of the findings  
6.2.1. The impact of hyperglycemia on stroke mortality  
The findings in rticle I showed that hyperglycemia and diabetes defined by either FPG or 2-
h  PG  increases  the  risk  of  stroke  mortality  both  in  women  and  in  men.  These  findings  
confirmed previous findings (Burchfiel et al., 1994; Hart et al., 1999; Kissela et al., 2005; 
Hu et al., 2005c; Hu et al., 2006; Mulnier et al., 2006) despite the differences in the 
methods used for the definition of hyperglycemia and diagnosis of diabetes. Several studies 
have reported hyperglycemia to increase the risk of CVD in non-diabetic individuals 
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(DECODE Study group, 2003a, Levitan et al., 2004; Lawlor et al., 2007). The oral glucose 
tolerance test has not been widely applied thus studies comparing the stroke risk between 2-
hour post-load hyperglycemia and fasting hyperglycemia are scarce. We found FPG to 
better predict stroke mortality in women and 2-h PG in men in subjects without diabetes at 
baseline.  
 
The underlying physiological base of IFG and IGT is different. Isolated IFG is mainly 
associated with hepatic insulin resistance and decreased first-phase insulin secretion, 
wheras isolated IGT is associated with peripheral insulin resistance and impairment of both 
early- and late-phase insulin responses (Abdul-Ghani, 2006). Men have been reported to 
have lower levels of beta cell function and higher prevalence of IFG compared with 
women, and women lower insulin sensitivity and higher prevalence of IGT compared with 
men (Williams et al., 2003).  Thus, the gender differences in stroke mortality related to IFG 
and IGT categories found in the present study could partly be exlained by the metabolic 
differences and differences in prevalence of IFG and IGT in women and men.  
6.2.2. The impact of hyperglycemia on the incidence of ischemic and hemorrhagic stroke  
A significant association was found between diabetes, both previously diagnosed and screen-
detected, and an increased risk of ischemic stroke in the present study (Article II). These results 
are consistent with other population based epidemiological studies (Janghorbani et al., 2007, 
Woodward et al., 2003). Increased risk of ischemic stroke has also been found in individuals 
with elevated serum fasting (Song et al., 2005) and nonfasting glucose levels (Lund-Håheim et 
al., 2006).  This study showed that in individuals without previous diagnosis of diabetes the 
risk of ischemic stroke increased with increasing FPG and 2-h PG levels. The risk was more 
significant for elevated 2-h PG compared with FPG levels. Studies have found an increased 
risk (Zia et al., 2005) of hemorrhagic stroke in individuals with diabetes diagnosed by fasting 
glucose levels, no association in individuals with overt diabetes (Inagawa et al., 2007) or with 
diabetes defined by 1- h postload glucose measurement (Burchfiel et al., 1994) or a decreased 
risk (Jorgensen et al., 1994; Megherbi et al., 2003) in individuals with overt diabetes. In the 
present study we found no relationship between hyperglycemia and the risk of hemorrhagic 
stroke. 
The etiology and pathophysiology of the ischemic and hemorrhagic stroke are different 
(Collins, 2007). Ischemic stroke is caused by impaired or cessation of blood flow to the brain, 
which may result in brain ischemia (Frosch et al., 2005), whereas hemorrhagic stroke results 
from a rupture in a cerebral blood vessel, which causes bleeding into the brain tissue (Collins, 
2007).  The main causes of acute ischemic stroke are large-artery atherosclerosis, caused by 
atherosclerosis in the internal carotid or vertebral-basilar arteries (Fisher et al., 2005), small-
vessel disease with formation of microatheroma in deep, small penetrating arteries and 
cardioembolism are the main causes of acute ischemic stroke (Fisher et al., 2008). 
Hypertension is a common cause for hemorrhagic stroke (Qureshi et al., 1997; Woo et al., 
2002; Ariesen et al., 2003). The different pathophysiology and etiology behind ischemic and 
hemorrhagic stroke could also indicate different risk factors for the two stroke sub-types and 
could explain the differences found in the present study between ischemic and hemorrhagic 
stroke. Further studies are needed to clarify the issue.  
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6.2.3. Age and gender difference in the incidence of coronary heart disease or stroke  
In the present study (Article III) we found mean BMI and total cholesterol levels to be higher 
in men than in women in younger ages (40-49 years at baseline), and similar in the middle age 
group (50-59 years) and somewhat lower in men than in women in the oldest age group (60-69 
years). In women HDL was higher compared with men in all age groups. Hypertension was 
more common in young men than in young women, but the difference leveled off in the oldest 
age group. The number of individuals with diabetes was higher in men than in women across 
age groups, but increased with age in both genders. Smoking was more common in men than in 
women.  
 
Men had a higher incidence of acute CHD and ischemic stroke compared with women at all 
ages. The difference between genders was more prominent for CHD than for ischemic stroke 
incidence. Compared with women aged 40-49 years the multivariate adjusted hazards ratios of 
acute CHD and ischemic stroke increased in older age groups in both genders, and were higher 
for men than for women given the same age. The gender difference in the hazard ratios was, 
however, smaller for ischemic stroke than for CHD. We found that aging was clearly 
associated with an increase in ischemic stroke, and this trend was more prominent in women 
than in men. The incidence of CHD and ischemic stroke were significantly higher (4.3 and 5.6 
times, respectively) in women in the oldest age group compared with the youngest age group; 
this age-related increasing trend in incidence of CHD and ischemic stroke was, however, less 
marked in men (3.4 and 4.3, respectively) than in women. We found a 10- year lag in the 
development  of  CHD  and  stroke  in  women  compared  with  men.  Our  findings  are  consistent  
with previous reports regarding gender difference in CHD and stroke incidence (Lerner et al., 
1986; Isles et al., 1992; Jousilahti et al., 1999; Rosamond et al., 2007). Both in women and in 
men age, smoking, diabetes and elevated cholesterol levels were risk predictors for CHD 
incidence. Additionally, 2-h PG was a CHD risk predictor in men and BMI in women. The risk 
predictors for the ischemic stroke incidence were otherwise similar, but elevated blood pressure 
instead of serum cholesterol levels was a significant risk predictor in both genders.  
 
Recent population based studies have found clear differences between risk factors for the 
diseases  of  the  circulatory  system  CHD,  stroke  and  peripheral  artery  disease  (Glynn  et  al.,  
2005; Wilhelmsen et al., 2005). Research has also indicated that different vascular sites may 
respond differently to different set of risk factors (DeBakey et al., 2000; Paraskevas et al., 
2008).  The Rotterdam Study found a more pronounced gender difference in the degree of 
atherosclerosis in coronary vessels compared with other vascular beds (Kardys et al., 2007). 
Thus, as also found in the present study, different risk factors could contribute differently in the 
development of CHD and stroke and these risk factors may differ by gender. The fact that 
fewer women smoked than men and the earlier exposure to the CVD risk factors in men and 
the more favorable HDL profile in women may also partly explain the gender difference found 
in the present study.  Other factors such as the menopause status (Andreotti, 2008) and 
transition (Janssen et al., 2008), the management of risk factors (Andreotti, 2008; Jairath, 2001; 
Stramba-Badiale, 2006) may also have contributed to the observed gender difference in CHD 
and ischemic stroke incidence, and need to be studied in more details.  
6.2.4. Age and gender difference in the incidence of coronary heart disease and ischemic 
stroke in diabetic and non-diabetic individuals       
The results in Article IV showed that both non-diabetic and diabetic men have a higher risk of 
CHD than their female counterparts, but the gender difference is not as pronounced in the 
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diabetic as in the non-diabetic populations. In contrast, diabetic men have higher rates of 
ischemic stroke events than diabetic women but the event rates do not differ much in the non-
diabetic population. Several studies have found diabetes to increase the risk of CHD (Jousilahti 
et al., 1999; Laakso et al., 2001; Howard et al., 2006) and stroke (Tuomilehto et al., 1996; Hart 
et al. 2000; Almdal et al., 2004) in both genders. Diabetes has been reported to increase the risk 
of CHD (Lee et al., 2000; Kanaya et al., 2002; Huxley et al., 2006) and stroke (Lehto et al., 
1996; Hart et al., 2000; Almdal et al., 2004) more markedly in women than in men. These 
studies have, however, used non-diabetic women and non-diabetic men as reference groups for 
women and for men, respectively, when they calculated the relative risk for diabetic 
individuals. In the present study in order to make the relative risk directly comparable between 
women and men, non-diabetic women in the youngest age group was used as a reference group 
for both women and men of all other age groups. Contradictory to the previous reports on 
stroke we found in the present study a more markedly increased risk of acute ischemic stroke 
events in diabetic men compared with diabetic women. But in the present study we could not 
examine whether this is true for hemorrhagic stroke or for the subtypes of ischemic stroke due 
to the low number of the hemorrhagic stroke events and inability of further classification of 
individuals into subtypes of the ischemic stroke. Previous studies with both ischemic and 
hemorrhagic stroke have shown a higher relative stroke risk in diabetic women than in diabetic 
men (Lehto et al., 1996; Hart et al., 2000; Almdal et al., 2004), Studies have also reported the 
risk of certain subtypes of ischemic or hemorrhagic stroke to differ between women and men 
(Roquer et al., 2003; Thrift et al., 2009). This might have affected the observations in the 
current study and needs to be explored in more detail in the future.  
 
In the present study we found non-diabetic men to have higher rates of smoking, hypertension 
and abnormalities of lipid profiles compared with non-diabetic women. This could partly 
explain the higher CHD risk in non-diabetic men compared with non-diabetic women. Also, 
other factors such as the menopause status (Andreotti et al., 2008) and the management of risk 
factors (Andreotti et al., 2008; Jairath et al., 2001) may have contributed to the observed gender 
difference in CHD and ischemic stroke incidence found in the present study. We found obesity 
and cholesterol levels to be higher in diabetic women compared with diabetic men, which may 
partly explain the smaller gender difference in CHD risk in diabetic population. Even though, 
CHD and stroke have some common aspects, the reactivity of coronary and cerebral arteries to 
the CVD risk factors, environmental and genetic factors, has been found to differ (Puddu et al., 
1995). Thus, as found in the present study the known CVD risk factors including diabetes may 
contribute differently to the development of CHD and the ischemic stroke, and partly explain 
the gender difference in the risk of CHD and ischemic stroke incidence found in diabetic 
individuals in the present study.  
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7 CONCLUSIONS 
The conclusions related to the study objectives are: 
1. In individuals without diabetes at baseline, the FPG criteria for diabetes compared 
with the 2-h PG criteria better predicted stroke mortality in women, whereas the 
latter was better than the former in men. The underlying pathophysiology of IFG 
and  IGT  is  different  and  the  prevalence  of  IFG  and  IGT  differs  between  genders.  
Thus, also the stroke mortality in relation to the two glucose categories may differ in 
between women and men.  
 
2. In individuals without a prior history of diabetes, elevated 2-h PG, but not FPG 
levels, predicted ischemic stroke incidence. Neither FPG nor 2-h PG predicted the 
incidence of hemorrhagic stroke. The different pathophysiology and etiology behind 
ischemic and hemorrhagic stroke could indicate different risk factors for the two 
stroke sub-types. Further studies are needed to clarify the issue.  
 
3. The relative risk of acute CHD and ischemic stroke was higher in men than in 
women  in  all  ages,  but  the  gender  difference  was  more  marked  for  CHD  than  for  
ischemic stroke. Aging and diabetes contributed to the development of CHD and 
ischemic stroke in both genders. BMI was a risk predictor for CHD incidence and 
hypertension and FPG for ischemic stroke incidence only in women. The 2-h PG 
predicted CHD and smoking predicted ischemic stroke incidence only in men.  
 
4. CHD risk was higher in men than in women but difference was not as pronounced in 
diabetic population. Diabetes, increased ischemic stroke risk more in men than in 
women. The proper understanding of reasons for the gender difference in CHD and 
ischemic stroke is important in developing effective interventions and treatment 
strategies for the two diseases.  
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Appendix 1. Information on blood glucose sampling and testing 
 
Population and 
code 
Blood sample Glucose load (g) 
 
Fasting time (hour)  Time of day of blood 
sampling (hour) 
Method of glucose assay 
Finland,  
East-West† 
Venous Plasma 75 overnight 8:00-10:00 am glucose dehydrogenase, (Beckmann, Brea, 
Ca. USA) 
National FINRISK 
Study  
Plasma 75 >8 8.00-11.00 am Hexokinase assay (Thermo Electron Oy) 
Helsinki Policemen 
Study†        
Venous whole blood 75    
Vantaa Venous whole blood? 75 overnight  Glucose oxidase (Beckman Instruments, 
Fullerton, California) 
Italy, Cremona Venous plasma  75, monohydrate  ?12 8:30-10:30 am GOD-PAP glucose-oxidase (Boehringer Mannheim, Milan, Italy) 
Malmö Preventive 
Project 
Plasma  75 overnight   
The Netherlands,  
Hoorn Study  
Venous Plasma 75, anhydrate ?10 8:00-10:00 am glucose dehydrogenase (Merck, Darmstadt, 
Germany) 
Zuthpen Study† Venous Plasma 75  overnight 8:00-10:00 am hexokinase (Abbott Epx) 
Sweden, MONICA Plasma 75 >10 7:45-10:00 glucose oxidase (Beckman analyzer)  
Uppsala† Venous Plasma 75   glucose dehydrogenase-photspectrometric 
(Gluc-DH, Merck, Darmstadt, Germany) 
U.K., Goodinge Plasma 75 overnight morning glucose-oxidase (Beckman, Brea, 
California) 
Newcastle Venous Plasma 75  overnight 8:00-10:00 am hexokinase (Abbott Epx) 
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Appendix 2. Information on lipid assays 
 
 
*venous whole blood for fasting sample in 55-year-old population 
Population and 
code 
Blood sample Triglycerides 
 
HDL  Cholesterol LDL Methodology 
Finland,  
East-West† 
venous Plasma + + + +  
National 
FINRISK Study  
Serum + + + - Enzymatic techniques (CHOD/PAP) Optima, Thermo 
Electron Oy 
Helsinki 
Policemen Study†       
venous whole blood + - + -  
Vantaa Serum + + + - Enzymatic techniques (Boehringer-Mannheim) 
Italy, Cremona venous Plasma + + + - Enzymatic techniques (Boehringer-Mannheim) 
Malmö 
Preventive 
Project 
plasma + - + -  
The Netherlands,  
Hoorn Study  
Serum + + + + Enzymatic techniques (Boehringer-Mannheim) 
Zuthpen Study† venous Plasma + + + -  
Sweden, 
MONICA 
Serum + + + - Enzymatic techniques (Boehringer-Mannheim) 
Uppsala† Serum + + + - Enzymatic techniques (Instrumentation 
Laboratories, Lexington, USA) 
HDL particles were separated by precipitation 
with magnesium chloride/phosphotumgstate. 
U.K., Goodinge plasma + + + +  
Newcastle venous Plasma + + + + Cobas Bio centrifugal analyser, Toch Products Ltd, 
UK 
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Appendix 3. Information on physical examination 
 
Population and code Blood pressure Waist Hip 
Finland,  
East-West† 
   
National FINRISK 
Study  
Mercury sphygmomanometer, Reister, cuff 
size 14*40 cm. 
Measured three times in sitting position 
from right arm of the subject. 
Midway between the lower rib 
margin and iliac crest 
Widest circumference over the greater 
trochanters 
Helsinki Policemen 
Study†        
   
Vantaa    
Italy, Cremona Sphygmomanometer (BP-103N, Japan), it 
was taken twice (beginning and end of 
visit), in the sitting position, after 10 
minutes rest and the lowest figure was 
considered 
Measured at the level of umbilicus Not measured; we measured thigh 
circumference at the level of the gluteal fold on 
the right thigh 
Malmö Preventive 
Project 
Sphygmomanometer, modifiable cuff width.   
Measured twice in the supine position after 
10 min rest. Mean figure was recorded 
  
The Netherlands,  
Hoorn Study  
On the right arm with sphygmomanometer 
(Hawksley_Gelman Ltd) 
Midway between the lower rib 
margin and iliac crest 
Widest level over the greater trochanters 
Zuthpen Study†    
Sweden, MONICA Random zero method Midway between the lower rib 
margin and iliac crest 
Maximum circumference over the buttocks 
Uppsala†  Midway between the lowest rib and 
the iliac crest 
Circumference over the widest part 
U.K., Goodinge    
Newcastle Measurements made following the protocol 
of the British Hypertension at the time of 
the study, so mercury sphyg with adult size 
cuff (12.5X32cm) for all. Right arm, sitting, 
mean of two measurements.  
Midpoint between the lower costal 
margin and the superior iliac crest 
Circumference over the greater trochanters 
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